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SUMMARY
The mechanism of Fas antigen-induced hepatocyte apoptosis was investigated. Using 
a monoclonal antibody directed against the Fas antigen, apoptosis was induced in 
freshly isolated murine hepatocytes within 90 minutes of antibody addition as 
assessed by plasma membrane bleb formation, chromatin condensation and DNA 
fragmentation. An established phenomenon is that of plated hepatocytes becoming 
refractory to the Fas ligand, reversible when the protein synthesis inhibitor, 
cycloheximide is administered. In order to elucidate by which mechanism this is 
regulated, various signalling protein inhibitors where used. The role of the MAPK as 
a negative regulator of Fas-mediated apoptosis was investigated using the MEKl 
inhibitor, PD089059. Inhibition of MEKl in conjunction with anti-Fas antibody 
induced apoptosis in cultured hepatocytes with similar kinetics to cycloheximide in 
combination with anti-Fas antibody. Both PD089059 and Wortmannin induced 
apoptosis in plated hepatocyte cultures in the absence of anti-Fas antibody. This 
study showed that the refractory nature of culture hepatocytes was due to the 
regulatory ability of constitutively synthesised proteins combined with one or both 
PI-3Kinase and MAPK activities rather than an adherence process.
Pre-treatment of the freshly isolated hepatocytes in cell suspension with the caspase 
peptide inhibitors, A-acetyl-Asp-Glu-V al-Asp aldehyde (Ac-DEVD-CHO), 
benzyloxycarbonyl-Val-Ala-jDZ-Asp-fluoromethylketone (Z-VAD-FMK) or Z-Asp- 
2,6-dichlorobenzoyloxymethyl-ketone inhibited anti-F as-mediated apoptosis. 
Likewise, the serine protease inhibitors, A-tosyl-L-phenyl chloromethyl ketone and 
3,4-dichloroisocoumarin prevented apoptosis, whereas A-tosyl-Z-lysine chloromethyl
m
ketone, Ac-Leu-Leu-L-norleucinal, Ac-Leu-Leu-L-methional and trans- 
epoxysuccinyl-L-leucylaniido-(4-guanidino)butane were without effect. Examination 
of CED-3/caspase-3-related caspases revealed that pro-caspases-3 (CPP32) and -7 
(Mch-3a) were rapidly processed after Fas antigen stimulation. Caspase-7 was 
further cleaved to form the catalytically active subunits. In contrast, the p i7 subunit 
of caspase-3 was not detected, indicating slow formation or rapid degradation. The 
activation of CED-3-related caspases was further confirmed by an increase in the rate 
of Z-DEVD-7-amino-4-trifluoromethylcoumarin (Z-DEVD-AFC) hydrolysis that was 
sensitive to Ac-DEVD-CHO and was inhibited by pre-treatment of the cells with N- 
tosyl-Z-phenyl chloromethyl ketone but not by 3,4-dichloroisocoumarin. In contrast, 
no increase in the rates of hydrolysis of Z-YVAD-AFC, a substrate for caspase-1, 
was detected. Investigation of the in situ proteolytic cleavage of the CED-3 related 
caspases substrate, poly (ADP-ribose) polymerase, revealed that this protein was not 
degraded in hepatocytes undergoing Fas-mediated apoptosis. Taken together, this 
study shows that processing of caspases, in particular, caspases-7 and -3 occurs 
during Fas-induced apoptosis of mouse hepatocytes and suggests a role of these 
proteases as well as serine protease(s) in the apoptotic response.
A cell-free system using isolated nuclei from liver and thymocytes together with 
hepatocyte and thymocyte apoptotic extracts was established to examine why liver PARP 
did not undergo proteolysis during apoptosis. The distinct morphological changes 
characteristic of apoptosis; chromatin condensation and DNA fragmentation, were seen in 
the nuclei incubated with apoptotic cell extract. In spite of these morphological and 
nuclear changes, apoptotic hepatocyte extract did not cleave PARP in thymocyte or liver 
nuclei but processed purified PARP to its 85 kDa fragment. However, incubation of
IV
apoptotic thymocyte extract with thymocyte nuclei resulted in rapid PARP cleavage, but 
failed to cleave liver PARP. Sonication of liver nuclei to liberate PARP did not render 
PARP cleavable by either extracts from apoptotic hepatocytes or thymocyte or even an 
excess of recombinant human caspase-3 activity. Take together this study showed that 
liver PARP is resistant to proteolytic cleavage by caspases and that the caspase-3/PARP 
machineiy is not requisite for apoptosis in Fas-mediated apoptosis in mouse hepatocytes.
The above findings showed that the refractory nature of cultured hepatocytes towards 
Fas receptor mediated apoptosis is owing to the activation of PI-3Kinases and 
MAPK. Further, the mechanism of Fas-induced hepatocyte apoptosis involves 
caspases, in particular caspase-7 and possibly caspase-3, as well as a TPCK/DCI 
sensitive serine-type proteases. The DNA-repair enzyme, PARP present in mouse 
liver is precluded from proteolytic cleavage by caspase-3 and related caspases which 
indicates that PARP proteolysis is not required for DNA fragmentation and the 
development of morphological features of apoptotic liver nuclei.
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Chapter 1
General Introduction
1.1 Apoptosis: Definition, Occnrrence & Roles
The term programmed cell death was introduced by developmental biologists as a 
technical term for the regulation of cell death and to explain cell death during 
embryogenesis (Ernst, 1926; Gliicksmannn, 1951; Lockshin and Williams, 1965; 
Saunders, 1966). The first report in cell death dates back to 1842. Subsequent 
studies documented the wide occurrence of cell death in insect and amphibian 
metamorphosis and also demonstrated its importance on vertebrate autogenesis 
(Clarke and Clarke, 1996). When Kerr, Wyllie and Currie observed a similar 
physiological form of cell death in adult animals, they called the phenomenon 
apoptosis, from ancient Greek, which means the falling of leaves and patels (Kerr et 
al., 1972). Since then, the area of apoptosis research has expanded rapidly and has 
now been shown to play a pivotal part in all vertebrae life and has even been found in 
plants and some unicellular organisms (Kerr et al., 1987; Arends and Wyllie, 1991; 
Ellis et al., 1991; Jacobson et al., 1997; Rudin and Thompson, 1997).
Apoptosis plays a pivotal role in embryogenesis, metamorphosis, maturation of 
immune systems as well as natural tissue turnover. Therefore, it forms an integral 
part of normal tissue homeostatic processes that control the number of cells present in 
an organ and so is the counterpart of mitosis, which is cell proliferation. In the 
immune system, apoptosis plays the role of killing mutated or cancerous cells, virally 
infected cells or autoreactive T-lymphocytes. Failure in the apoptotic process leads 
to disorders such as cancers e.g. lymphoid malignancies (Nagata, 1994) or 
autoimmune diseases e.g. humans systemic lupus erythematosus (Mysler et al.,
1994). Alternatively, apoptosis may directly induce disorders when overstimulated
such as AIDS (Singer et al., 1994), diabetes (Chervonsky et al., 1997), Parkinson’s 
syndrome and Alzheimer’s disease (Thompson, 1995).
1.2 Characteristics of Apoptosis
Apoptosis was originally distinguished by its morphological changes and only 
recently has there been a greater understanding in the biochemical changes that occur. 
All these changes have been used to differentiate apoptosis and necrosis, which is 
uncontrolled cell death occurring as a result of massive tissue injury (Table I).
Changes Apoptosis Necrosis
Stimuli Physiological Pathological (injury)
Occurrence Single cells Groups of cells
Reversibility No (after morphological 
changes)
Yes (up to the point of no 
return)
Adhesion between cells and to 
basement membrane
Lost (early) Lost (late)
Cytoplasmic organelles Late stage swelling Very early swelling
Lysosomal enzyme release Absent Present
Nucleus Convolution of nuclear outline 
and breakdown (karorrhexis)
Disappearance (karyolysis)
Nuclear chromatin Compaction in uniformly dense 
masses
Clumping, not sharply defined
DNA breakdown Intemucleosomal Randomised
Cell Formation of apoptotic bodies Swelling and later disintegration
Phagocytosis by other cells Present Absent
Exudative inflammation Absent Present
Scar formation Absent Present (dependent on tissue)
Table 1: Differentiation between Apoptosis and Necrosis.
This table summarises in broad terms the differences between apoptosis and necrosis.
1.3 Morphological Features of Apoptosis
One of the first changes seen in apoptosis is cellular shrinkage and detachment from 
neighbouring cells. Alongside, are seen changes in the plasma membrane resulting in 
small protrusions, known as blebs (Fig. 1) (Kerr et al., 1987; Arends and Wyllie, 
1991). Also, there can be seen condensation of the nuclear chromatin with nuclear 
shrinkage (Fig. 2), resulting in margination of the nucleus at the periphery (Eamshaw 
1995). Subsequently, the nuclear envelope breaks up and nucleus fragments begin to 
form into discrete chromatin containing bodies called apoptotic bodies (Fig. 3). 
These apoptotic bodies also contain intact cytoplasmic structures and other 
organelles, which can be seen by electron microscopy (Kerr et al., 1972; Arends and 
Wyllie, 1991). In some cell types, such as hepatocytes or Jurkat T-lymphocytes, 
these apoptotic bodies remain within the cell structure stabilised by a rigid plasma 
membrane, whereas cells like thymocytes, they readily break off and are engulfed by 
phagocytic cells. Although the mechanistic basis to the morphological changes in 
apoptosis is only now becoming clear, we should not forget that the key 
morphological features that characterise an apoptotic cell have been known since the 
19^  ^century (Clarke and Clarke, 1996).
AFigure 1: Morphological changes in Jurkat T lymphocytes undergoing apoptosis 
as revealed by phase contrast light microscopy.
Apoptosis was triggered by activating the Fas death receptor with a monoclonal 
antibody. The Jurkat cells were treated with anti-Fas antibody (250 ng/10^ cells) and 
after morphological effects were monitered using light microscopy. The top 
photograph (A) shows control, non-apoptotic cells while in (B) the classical features 
o f apoptosis (cell shrinkage, plasma membrane blebbing) are clearly visible after 
treating cells with anti-Fas antibody for one hour.
BA
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Figure 2: Nuclear changes in apoptotic Jurkat T-Lymphocytes
Apoptosis was triggered by activating the Fas death receptor using a monoclonal 
antibody. Jurkat cells were treated with anti-Fas antibody (250 ng/10^ cells(for 60 
and 180 minutes. Aliquots o f the cell suspension were fixed and processed for  
examination by confocal laser scanning microscopy (A,C,E) or transmission electron 
microscopy (B,D,F). For confocal laser scanning microscopy, the chromatin was 
visualised by staining its DNA with the fluorescent probe, propidium iodide. The 
chromatin, which is diffusely distributed in untreated control cells (A,B), rapidly 
condenses at the nuclear envelope after one hour o f treatment with anti-Fas antibody 
(C,D) followed by the formation o f discrete apoptotic bodies after three hours (E,F). 
Bars correspond to 5 pm (left panel) or 1 pm (right panel).
Figure 3: Formation of apoptotic bodies.
Morphological changes o f apoptosis induced by anti-Fas antibody treatment in 
murine hepatocytes. Hepatocytes were incubated for 3 hours in the presence o f anti- 
Fas antibody (100 ng/mL), then visualised using light microscopy. Bar = lOOjitm.
1.4 Biochemical Features of Apoptosis
There have been numerous discoveries in the various biochemical changes that occur 
within an apoptotic cell. A key event that occurs is the degradation of nuclear DNA, 
which is initiated early in apoptosis by the cleavage of DNA into distinct high 
molecular weight fragments (Fig. 4), corresponding to >700 kilobase pairs (kbp). 
These fragments are then further degraded to 200-250 and 50 kbp fragments 
(Oberhammer et al., 1993) and then finally to oligonucleosomal DNA fragments 
which produce a ladder formation when resolved by agarose gel electrophoresis
(Fig. 5) (Wyllie, 1980; Arends and Wyllie, 1991). In contrast, mitochondrial DNA 
remains intact during apoptosis (Murgia et al., 1992). Of note is that cleavage of 
DNA to HMW fragments has been observed in some forms of necrosis (Bicknell and 
Cohen, 1995), and that key morphological features of apoptosis may occur in the 
absence of intemucleosomal DNA fragmentation. The actual identity of the 
endonuclease(s) that cleave DNA is still not fully known. The formation of HMW 
fragments is mediated by an Mg^ "^ - and Ca^^- requiring endonuclease (Cain et al., 
1994; Sun and Cohen, 1994; Zhivotovksy et al., 1994) that appears to be different 
from the endonuclease(s) that further degrades the fragments to nucleosomal and 
oligonucleosomal-sized fragments. A recent report has emerged of an endonuclease 
referred to as caspase-activated deoxyribonuclease (CAD) that is located in the 
cytosol, where it is found bound to a specific inhibitor (ICAD). When ICAD is 
proteolytically cleaved during apoptosis (Sakahira et al., 1998), CAD is freed and 
enters the nucleus where it will cleave DNA (Enari et al., 1998). Again, the exact 
process is unknown, though research is being undertaken to elucidate the mechanism. 
Recently, a protein was identified and purified from HeLa cytosol that induced DNA 
fragmentation in co-incubated nuclei after protease activation (Liu et al., 1997) called 
DNA fragmentation factor (DFF). DFF is a heterodimer of 40 kDa and 45 kDa 
subunits of which the 40 kDa subunit was shown to induced DNA fragmentation and 
chromatin condensation during apoptosis (Liu et al., 1998).
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Figure 4: DNA degradation during apoptosis as assessed by the formation of 
high molecular weight fragments.
Jurkat cells were treated with anti-Fas antibody (250 ng/10^ cells) and at the 
indicated time points were processed for the examination o f high molecular weight 
DNA fragments by field  inversion gel electrophoresis (FIGE). Three major bands 
corresponding to fragments o f sizes >700 kbp, 200-250 kbp and 50 kbp become 
visible in the apoptotic cells, starting 45 min after anti-Fas antibody treatment.
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Figure 5: DNA degradation during apoptosis as assessed by the formation of 
oligonucleosomal-length fragments.
DNA degradation during apoptosis as assessed by the formation o f  
oligonucleosomal-length fragments. Jurkat cells were treated with anti-Fas antibody 
(250 ng/10^ cells) and at the indicated time points were processed fo r  the 
examination o f low molecular weight DNA fragments by conventional agarose gel 
electrophoresis. The degradation o f DNA correlates with the appearance o f  the 
typical DNA “ladder”.
Other biochemical features that occur in the apoptotic process are degradation of the 
cytoskeletal components such as nuclear lamina (Takahashi et ah, 1996) and actin 
(Brown et al. 1997; Mashima et al. 1995). Indeed, disruption of microtubules was 
found to induce apoptosis in HL-60 cells (Martin and Cotter, 1990), and that 
microfilament-disrupting agents prevented the formation of apoptotic bodies (Cotter 
et al., 1992). A distinctive feature of apoptosis is that cells are removed without 
leakage of intracellular components, possible as a result of membrane stabilisation 
via transglutaminase activation that cross-links cytoplasmic proteins (Fesus et al., 
1987). Exposed phosphatidylserine (which usually resides on the inner membrane 
leaflet), and carbohydrate changes on apoptotic cells have been shown to be 
connected with recognition of apoptotic fragments by integrins and lectins on 
macrophages (Fadok et al., 1992). It has been since shown that proteases are 
involved in fodrin cleavage and phosphatidylserine exposure in apoptosis (Vanags et 
al., 1996). Also, the extracellular matrix protein vitronectin has been shown to be 
responsible for binding apoptotic human neutrophils (Savill et al., 1990) and as such 
may serve a function as specific cellular recognition. Indeed the distinctive 
recognition pathways used by macrophages for binding apoptotic neutrophils may 
represent a control point in the physiological termination of the acute inflammatory 
reaction (Savill et al., 1989).
Ceramides have been implicated as another biochemical characteristic of apoptosis 
(Hannun & Obeid 1995; Hannun 1996) which can be inhibited by sphingosine-1- 
phosphate (Cuvillier et al., 1996). However, the involvement of ceramides in 
apoptosis is still in contention as many reports have shown the lack of involvement of 
ceramides (see e.g. Hsu et al., 1998). It appears the variations lie in the apoptotic
10
inducer and the cell type as to the involvement of sphingomyelin-ceramide turnover. 
Evidence for changes in calcium homeostasis in apoptosis have been shown (Kass 
and Orrenius, 1999). Some inducers of apoptosis, such as the Ca^ "^  pump inhibitor 
thapsigargin cause a sharp elevation in intracellular calcium though changes in Ca^  ^
levels are not seen in all models of apoptosis. Calcium is implicated in playing a role 
in the control of cytoskeletal components, such as actin, or through the activation of 
calcium-dependent proteases of the calpain family (a multi-functional protease that 
activates other enzymes in a calcium dependent manner), and calcineurin (a 
serine/threonine phosphatase). Owing to the discrepancies arising from the various 
reports as to the role of calcium in apoptosis, there may be two pathways, a calcium 
dependent and independent pathway, arising from the differing cell types and stimuli 
used.
1.5 Intracellular Mediators of Apoptosis
Initially, the model used for the study of apoptosis was the nematode Caenorhabditis 
elegans (C. elegans). In the development of the organism 1090 cells are generated, 
of which 131 cells die by apoptosis after a precisely determined series of divisions. 
Genetic studies in the C. elegans have identified several intracellular mediators of the 
apoptotic pathway. The nematode ced-9 gene was discovered by gain-of-function 
mutational studies and was shown to protect cells from undergoing apoptosis 
(Hengartner et al., 1992). In contrast loss-of-fimction mutational studies showed that 
the ced-3 gene caused all 131 cells that normally undergo apoptosis to survive 
implicating that ced-3 is required for apoptosis (Ellis and Horvitz, 1986). Also loss-
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of-function mutations showed that the gene ced-4 is required for the apoptotic 
process. The regulatory genes have been shown to have mammalian homologues.
1.5.1 CED-9
The ced-9 gene encodes a protein with significant homology to the vertebrate Bcl-2 
and B c1-x l survival proteins (Hengartner and Horvitz, 1994). The bcl-2 gene product 
is expressed in the nuclear envelope, endoplasmic reticulum and the inner 
mitochondrial membrane and appears to be restricted to cells that can undergo 
apoptosis. Subsequent to the discovery of bcl-2, a variety of genes capable of 
regulating cell death have been identified, including bcl-x, bax, A l, MCLl, bak and 
bad which all exhibit significant sequence homology to bcl-2. Some bcl-2 
homologues such as bcl-x^ function as death suppressors (Boise and Thompson, 
1997), whilst others such as 6c/-X g , bax (Oltvai et al., 1993) and bad (Yang et al.,
1995) function as death promoters. The activity of bcl-2 appears to be controlled by 
bax, which exists as a homodimer and is capable of forming heterodimers with bcl-2 
(Oltvai et al., 1993). The expression of bax inhibits bcl-2 function and leads to cell 
death. It appears that there is an almost cyclic regulatory mechanism by which these 
regulatory gene products control apoptosis, as most can form hetero or homodimers 
and its these interactions that determine the cells fate (Korsmeyer, 1995). A 
relatively recent homologue was identified, bag-l which appears to be capable of 
working in concert with bcl-2 (Takayama et al., 1995) which has since been shown to 
regulate a chaperone protein (Hohfeld and Jentsch, 1997).
1.5.2 CED-4
The human homologue of ced-4 remained unidentified until very recently even 
though it was known that in C. elegans, ced-4 functioned as an activator or effector of
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the cell death machineiy (Yuan and Horvitz, 1992) and that it interacted with ced-3 
and ced-9, creating a biochemical framework of cell death (Chinnaiyan et al., 1997; 
Wu et al., 1997). Finally, Apaf-1, a mammalian homologue to ced-4 was identified 
(Zou et al., 1997) which has since been shown to interact with the mammalian 
homologues to ced-3 and ced-9 (Hu et al., 1998).
1.5.3 CED-3
The human homologue to ced-3 was characterised as the interleukin-1(3 converting 
enzyme (ICE) (Yuan et al., 1993) which is responsible for converting inactive pro- 
inflammatory cytokine pro-interleukin-Ip in monocytes (Black et al., 1989). When 
overexpressed, ICE was found to induce apoptosis suggesting that it plays a central 
role in the apoptotic pathway (Miura et al., 1993). Further evidence to support the 
hypothesis of the involvement of ICE-like proteases, was the ability of specific 
natural protease inhibitors, including the cowpox viral serpin CrmA (Tewari and 
Dixit, 1995) and baculovirus p35 (Qi et al., 1997), to inhibit apoptosis. Since the 
discovery of ICE in apoptosis, a whole myriad of ICE-like proteases has been 
identified resulting in a unified nomenclature (Table 2). The name proposed for this 
rapidly expanding family of ICE-like proteases, of which there are now at least 14 
members, was caspases as the ç refers to the cysteine protease and the aspase refers to 
the preferential cleavage site of the enzyme after an aspartate residue (Alnemri,
1997). The varying numbers refers to the order of publication so ICE becomes 
caspase-1. Phylogenetic studies have shown that the caspases comprise three 
subfamilies, which are an ICE subfamily (caspases-1, -4, and -5), a ced-3/CPP32 
subfamily (caspases-3, -6, -7, -8, -9, and -10) and an ICH-1/Nedd2 subfamily
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(caspase -2). When overexpressed in mammalian cells, all cloned caspases induced 
apoptosis.
1.5.4 Caspases
Caspase-1 and caspase-3 have been purified firom natural sources, cloned and 
structures determined by X-ray crystallography (Nicholson et al., 1995; Walker et al., 
1994; Rotonda et al., 1996). These highlighted a number of distinguishing catalytic 
and structural properties. Like many other proteases, caspases are synthesized as 
inactive pro-enzymes, which are proteolytically cleaved at specific aspartate residues 
to form the mature form. The catalytic domain is a heterodimer composed of a large 
subunit of 17-21 kDa and a smaller subunit of 10-13 kDa. It has been shown by X- 
ray crystallography in caspase-1 and caspase-3, that the two heterodimers associate to 
form a tetradimer (Wilson et al., 1994). Within each heterodimer, the two subunits 
are tightly associated to form a single catalytic domain composed of a central six- 
stranded p sheet core flanked on either side by a  helices. The active site 
pentapeptide, which lies in a groove on the surface of the enzyme, is comprised of 
residues from both large and small subunits and contains the general structure 
QACXG (where X is R, Q or G). Caspases are among the most specific of proteases 
having an absolute specificity for aspartic acid in the Pi position. This is owing to the 
amino acids Cys-285 and His-237 that are involved in catalysis and those involved in 
the ?i carbohydrate binding pocket (Arg-179, Gln-283, Arg-341 and Ser-347) being 
conserved in all caspases save for caspase-8 where Thr is substituted for Ser-347. 
However, the residues that form the P 2 - P 4  binding pocket are not well conserved in 
caspases suggesting the variations in substrate specificities. It has recently been 
shown that the substrate primary sequence recognition by caspases is required for
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catalysis and hence divides these proteases into three groups according to substrate 
specificities (Rano et al., 1997; Thomberry, 1997). Group 1 caspases (-1, -4 and-5) 
favour the sequence Trp-Glu-His-Asp (WEHD), whilst group 2 caspases (-2, -3, -7 
and ced-3) prefer the sequence Asp-Glu-X-Asp (DEXD). Group 3 caspases (-6, -8, - 
10) are not as specific but have a marked preference for branched, aliphatic side 
chains and hence an optimal sequence of (Val, Leu)-Glu-X-Asp ((V, L)EXD). It has 
been extensively shown that endogenous substrates for caspases are cleaved at sites 
that are similar or identical to the previously determined optimal sequence sites, with 
varying rates of cleavage (Km) that are not so dissimilar to their tetrapeptide 
substrates. Hence the biological relevance of the caspases can be determined.
Role o f Caspases
It would appear that group 1 caspases act as mediators of the inflammatory process, 
group 2 caspases are mediators of the effector phase of apoptosis and group 3 
caspases are involved in the signaling pathway where they act upstream of the 
effector caspases. The role of caspases in a signaling pathway has been well 
researched showing that caspases are involved in the apoptotic pathway mediated by 
varying effectors (Cohen, 1997; Nicholson and Thomberry, 1997; Thomberry, 1998). 
It has been postulated that caspases proteolytically cleave other specific caspases and 
thus activate them inducing a caspase cascade, resulting in cell death.
Caspase Substrates
During the apoptotic process, various endogenous substrates have been identified as 
being proteolytically cleaved by specific caspases with varying affinities, such as 
nuclear lamina (Takahashi et al., 1996) cleavage of which is linked to chromatin
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condensation, the inhibitor of caspase-activated DNase (ICAD/DFF45) (Enari et ah,
1998) which is involved in degradation of nuclear DNA, sterol regulatory element- 
binding protein (Wang et ah, 1995), and the 70 kDa protein component of the U1 
small nuclear ribonucleoprotein (Casciol-Rosen et ah, 1994; Tewari et ah, 1995) 
which is essential for splicing of precursor mRNA. A recent study showed that 
chromatin condensation and DNA fragmentation are mediated by the activation of 
DFF, a heterodimeric protein consisting of a 40-kDa (DFF40) and a 45-kDa unit 
(DFF45,) by caspase-3 (Liu et ah, 1998).
The best characterised caspase substrate is the DNA repair enzyme, poly (ADP- 
ribose) polymerase (PARE) which has been used as a universal hallmark for 
apoptosis (Kaufinann et ah, 1993; Lazebnik et ah, 1994; Endres et ah, 1997; 
Shiokawa et ah, 1997) in many models. The enzyme is a zinc binding protein and 
binds to DNA via two zinc fingers with very high affinity (De Murcia and De 
Murcia, 1994). PARP uses NAD"  ^as a substrate, linking poly (ADP-ribose) moieties 
to cleavable sites in DNA, thus allowing structural integrity to be maintained until 
permanent repairs can be undertaken by DNA polymerase (Althaus and Richter, 
1987). The enzyme is present in the cytosol as a 116 kDa precursor protein which on 
proteolytic cleavage is degraded to 24 kDa and 85 kDa subunits, representing the N- 
terminal DNA binding domain and the C-terminal catalytic domain. Most if  not all 
inducers of apoptosis have been shown to lead to PARP cleavage during apoptosis 
and consequently widely accepted as a marker of apoptosis. It is now established that 
in cells undergoing apoptosis, caspase-3 is responsible for the proteolytic cleavage of 
PARP (Tewari et ah, 1995), although PARP cleavage has also been obtained using 
caspases including -4 , -5, -7 and -8  in vitro through cleavage at the DEVD
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recognition site (Nicholson and Thomberry, 1997; Alnemri, 1997; Nicholson et al., 
1995; Cohen, 1997). Other caspase substrates are certain cytoskeletal components 
such as fodrin (Cryns et al., 1996; Vanags et al., 1996), actin (Mashima et al., 1995; 
Kayalar et al., 1996; Brown et al., 1997), Gas2 (Brancolini et al., 1995) and keratins 
(Oishi et al., 1994). Cleavage of these components may lead to cellular shrinkage 
and membrane blebbing. The caspases responsible for cleavage of these various 
substrates are shown in Table 2, but it is still not fully understood as to their 
biological significance in terms of either the substrates or the caspases. Are the 
caspases compartmentalised and is this related to the localisation of their specific 
substrates? Other issues to address are whether certain caspases are made redundant 
as some caspases share the same substrates and whether this is tissue specific. Also 
is the processing of the various substrates needed for the apoptotic process or are they 
merely innocent bystanders that have the relevant cleavage signature?
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New Name Old Name Preferred small 
substrate
Known or presumed polypeptide 
substrates
Caspase-1 ICE YEVDx>YVADx Pro-IL-ip, PITSLRE kinase o2-l
Caspase-2 Ich-lL YDVADx Not PARP
Caspase-3 CPP32. Yama, 
apopain
DMQDx>DEVDx PARP, DNA-PKcs, PKÔ, actin, 
Gas2, PAK2, Procaspase-6 and -9, 
MDM2, C1/C2 HnRNP, 70kDa U1 
SnRNP, PITSLRE kinase a2-l
Caspase-4 Tx/Ich-2, ICE,ei-ll LEVDx>YEVDx Pro-Caspase-1
Caspase-5 IC E ,ei-lll,T Y Unknown Not pro-IL-ip
Caspase-6 Mch2 VEIDx Lamins A/C and B
Caspase-7 Mch3, CMH-1, ICE- 
LAP3
DEVDx>DMQDx PARP, C1/C2 HnRNP
Caspase-8 Mch5, MACH, 
FLICE
lETDx Procaspase-3,-4,-7 and -9
Caspase-9 Mch6, ICE-LAP6 Unknown
Caspase-10 Mch4 lEADx Procaspase-3 and -7
(adaptedfrom Villa et al, 1997)
Table 2: Selected properties of caspases
Refer to text fo r  description
Owing to identification of caspase recognition sites, exogenous substrates and peptide 
inhibitors have been formulated. Reversible inhibitors include ketones, aldehydes, 
and nitrites, whereas irreversible inhibitors include a-substituted ketone, and include 
diazomethylketones, halomethylketones and acyloxymethylketones. All these 
compounds have been used to study the role of caspases in intracellular signalling 
pathways and will be discussed later.
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1.5.5 Non-caspase Proteases
Other proteases that are not caspase have been implicated in the apoptotic signalling 
pathway. Granzyme B is a serine protease that cleaves at Asp-X bonds (Poe et al., 
1991), rendering it a unique serine protease and has been shown to be required for 
cytotoxic T cells to induce apoptosis in target cells (Heusel et al., 1994). Recent 
reports have shown that granzyme B activates several members of the caspase family 
(Martin et al., 1996; Shi et al., 1996; Medema, et al. 1997a). In the presence of 
perforins, granzyme B upregulates the activity of a cyclin-dependent kinase (Shi et 
al., 1994) which has recently been shown to be activated by a caspase-3 dependent 
pathway (Shi et al., 1996; Medema et al., 1997a). Calcium-dependent neutral 
cysteine endopeptidases (calpains), which are involved in membrane and cytoskeletal 
changes in various other cellular changes, have also been implicated in the apoptotic 
pathway in various models (Bronk and Gores, 1993; Squier and Cohen, 1997) though 
this remains at present unclear. Again, these proteases have been studied 
experimentally by the use of specific protease inhibitors. Serine protease inhibitors 
effectively prevented the anti-Fas induced changes in cellular morphology as well as 
DNA degradation in Jurkat cells which implies the role of serine proteases in Fas- 
mediated apoptosis (Weis et al., 1995). Inhibition of serine protease in a cell fi*ee 
system also resulted in inhibition of anti-Fas induced changes (Chow et al., 1995). 
Supernatants prepared firom these cells (non-apoptotic) did not induce chromatin 
cleavage when incubated with thymocyte nuclei. A 24 kDa apoptotic serine protease 
(AP24) purified from U937 cells was shown to activate DNA fragmentation during 
apoptosis (Wright et al., 1994). Finally, the 26S proteasome has also been implicated 
as playing a role in apoptosis (Hirsch et al., 1998). This enzyme is a highly
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conserved multicatalytic proteolytic complex present in all eukaryotic cells and is 
responsible for the degradation of most cellular proteins (Hochstrasser, 1995).
1.6 The role of Mitochondria in Apoptosis
The mitochondria have been shown to be affected by the cell death program. Many 
studies have shown that there is a partial depolarisation of the mitochondria 
membrane potential in apoptotic cells (Cossarizza et al., 1994; Shidoji et al., 1997) 
though this has also been seen in necrosis (Kass et al., 1992; Aguilar et al., 1996). A 
recent flurry of research has now shown that mitochondria play an important role in 
the regulation of apoptosis (Kroemer et al., 1997; Kroemer et al., 1998; Mignotte and 
Vayssiere, 1998). During the apoptotic process, the mitochondrial inner membrane 
potential (A\|/m) is frequently disrupted before caspases and endonucleases are 
activated. This drop in A\|/m is prevented by agents that inhibit the mitochondrial 
megachannel, also known as the permeability transition (PT) pore. The pore 
diameter is around 2.3 nm which allows movements of molecules up to 1,500 Da, and 
traverses across the inner and outer mitochondrial membrane (Crompton and 
Carafoli, 1979; Kroemer et al., 1997). The mitochondrial permeability transition pore 
comprises an adenine nucleotide translocator, a voltage-dependent anion channel, 
cyclophilin D (as a matrix) and the apoptosis regulatory protein, Bax. The pore 
participates in the regulation of matrix Ca^ "^ , pH, Aij/m and volume, functioning as a 
Ca^^-, voltage-, pH- and redox-gated channel (Bemardi and Petronilli, 1996). The 
opening of the pores allows equilibrium of ions and respiratory substrates between 
cytoplasm and mitochondrial matrix leading to a reduction of the A\|/m and the arrest 
of ATP synthesis (Bemardi et al., 1992). There are many activators of the pore such 
phosphates and prooxidants in the presence of Ca^ "^ , high concentrations of Ca^^, a
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low A\|/m, thiol-modifying agents and atractyloside. Inhibitors of the pore include 
cyclosporin A, ADP, Mg^ "^ , high antioxidants and bonkrekic acid. It has since 
been shown that the bcl-2 gene product can impose a block on the induction of the 
mitochondrial permeability transition that accompanies a reduction in the 
mitochondrial membrane potential and correlates with an impairment of PT- 
associated apoptosis (Green and Kroemer, 1998). Cytochrome c release from 
mitochondria appears to have an important role in apoptosis. Cell-free assays of 
caspase activation have shown that cytochrome c induces pro-caspase-3 cleavage and 
that there is a release of cytochrome c from mitochondria into the cytoplasm during 
the inner mitochondrial membrane permeability transition associated with apoptosis 
(Kluck et al., 1997). Recent evidence has shown that cytochrome c interacts with 
Apaf-1 (the mammalian homologue of ced-4) and caspase-9 to activate pro-caspase-3 
proteolytically (Hengartner, 1997; Zou et al., 1997), thus constituting an apoptosome. 
The mitochondrial release of cytochrome c during apoptosis appears to be regulated 
by bcl-2 (Yang et al., 1997). However, there are many questions concerning the role 
of cytochrome c and mitochondria in the apoptotic process, which are as yet 
unanswered. Initially the absence of mitochondrial changes was considered as a 
hallmark of programmed cell death (Kerr and Harmon, 1991), whilst now 
mitochondria are sometimes presented as the central executioner of apoptosis 
(Golstein, 1997; Kroemer et al., 1997) even though there are no morphological 
changes in mitochondria and the mitochondrial permeability transition pore inhibitor, 
cyclosporin A does not inhibit apoptosis. Also, there is a rapid drop in cellular ATP 
levels which lead to the cells becoming committed to necrosis as the presence of ATP 
is required for at least some of the features of apoptosis (Kass et al., 1996; Leist et al., 
1997a).
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1.7 Inducers of Apoptosis
There are many differing signals that induce apoptosis in varying cell types that can 
be grouped into the following areas:
1. Therapeutic Agents
2. Toxins
3. Damage-related inducers
4. Physiological Inducers
Therapeutic agents include anticancer drugs that are used to induce apoptosis in 
rapidly proliferating normal cell population, lymphoid tissues and tumours (Hickman 
et al., 1992; Eastman et al., 1994). This has been observed both in vitro (Tomei et al., 
1988; Kaufmann, 1989; Walker et al., 1991; Bruno et al., 1992; Zhivotovsky et al., 
1993; Ormerod et al., 1994) and in vivo (Gorczyca et al., 1993; Su et al., 1993; Meyn 
et al., 1994; Meyn et al., 1995; Moreira et al., 1995; Decaudin et al., 1997). The 
ability of anticancer drugs to induce apoptosis appears to be unrelated to their 
intracellular target(s). For example, apoptosis occurs in cells exposed to 
topoisomerase I and II inhibitors (e.g., etoposide, camptothecin), microtubule poisons 
(e.g., colchicine, taxol) and DNA damaging agents (e.g., adriamycin, cis-platinum, 
nitrogen mustard, cyclophosphamide) by inhibition of progression through the cell 
cycle. Other examples of apoptosis-inducing therapeutic agents are gamma radiation 
and UV radiation (Kerr et al., 1994).
A rapid loss in cell viability is observed when cells are exposed to excessive 
concentrations of a cytotoxic agents. However, under more controlled conditions, the 
same agent may be capable of inducing apoptosis. Toxic chemicals that generate
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oxidative stress or induce a pathological increase in cellular calcium levels can kill 
their target cells by necrosis or by apoptosis, depending on the degree of exposure 
(Dypbukt et al., 1994; Bonfoco et al., 1995; Raffray and Cohen, 1997).
Cell growth and survival factors such as interleukins, nerve growth factor or 
epidermal growth factor maintain their affects via cell surface receptors and are 
essential for their target cell survival. Their withdrawal induces cell death by 
apoptosis (Baffy et al., 1993; Yu et al., 1993). However, there are many 
physiological inducers of apoptosis that exert their affect by interacting with cell 
surface receptors, thus inducing a signalling cascade. Examples are 
neurotransmitters, transforming growth factor p and members of the tumour necrosis 
family (Wyllie, 1980; McConkey et al., 1989; Brown et al., 1993; Jacobson et al., 
1997; Nagata, 1997; Rudin and Thompson, 1997). The cell surface type I membrane 
proteins, tumour necrosis family (TNF) receptors encompass a large superfamily of 
receptors, of which there are over 12 members to which we can associate over 8 
TNF-related cytokines (Table 3). The distinctive but overlapping cellular responses 
and their interactions produce clearly defined developmental and regulatory networks 
involving cells of the lymphoid, haematopoetic and other systems. All members of 
this family share common structural features in their extracellular regions, such as 
multiple cysteine-rich domains. Members of this family include two TNF receptors 
(the 55 kDa type I and the 75 kDa type II), the nerve growth factor (NGF) receptor, 
the B-cell antigen CD40, the T-cell antigen 0X40, CD28, 4-IBB, the Hodgkin’s 
lymphoma cell-surface antigen CD30 and Fas (CD95/APO-1). The TNF group has 
been extensively studied, and has numerous functions, including cytotoxic and 
proliferative activities (Smith et al., 1994).
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t i în n m rJ  D D
cysteine-rich domain
DR3 DR4 DR5 FasR T N F-R IT N F-R II NGF-RII CD40 CD27 CD30
Table 3: TNF-Receptor Superfamily
(adaptedfrom Holmstôm, 2000)
Several receptors with important function in differentiation, survival, and apoptosis 
belong to the emerging TNF R superfamily. Some members o f  the TNF R superfamily 
are able to induce apoptosis and contain a death domain in the cytosolic part o f  the 
receptor. Several members, however, have other functions such as induction o f  
proliferation and differentiation.
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1.8 The Fas System
1.8.1 The Fas Receptor
The Fas receptor (FasR) is a 45 kDa protein belonging to the TNF receptor family 
(Nagata, 1994) comprising of 335 amino acids. The human Fas gene has been 
mapped to the long arm of chromosome 10 and the mouse to chromosome 19 
(Watanabe-Fukunuaga et al., 1992; Cheng et al., 1995). Fas is a type I 
transmembrane protein, of which the cytoplasmic domain of Fas consists of 145 
amino acids, in which no motif for enzymic activity such as kinases or phosphatases, 
can be found. A region of sequence homology between Fas and TNFRl of 80 amino 
acids in the cytoplasmic domain suggest that this region is responsible for the death 
signal and further work has shown this to be the case and hence termed the death 
domain (Itoh and Nagata, 1993; Targlia et al., 1993). The death domain has a 
tendency to self-aggregate, and the tertiary structure of the Fas death domain shows 
that the death domain is a novel protein fold consisting of six antiparrallel, 
amphipathic a helices (Huang et al., 1996). Many charge amino acids are present on 
the surface, which is probably responsible for mediating the interactions between the 
death domains described later. The Fas antigen has been shown to be expressed in 
the heart, lung, lymphoid system and the liver (Krammer et al., 1994). A soluble 
form of the Fas receptor (sFas) was isolated (Cheng et al., 1994), and shown to block 
Fas-mediated apoptosis. Subsequent studies have shown elevated levels of sFas in 
patients with systemic lupus erythematosus (Jodo et al., 1997) and other autoimmune 
disorders.
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1.8.2 The Fas Ligand
The Fas ligand (FasL) is a type II transmembranous protein, in that its N-terminus is 
in the cytoplasm and its C-terminal region extends into the extracellular space, that 
belongs to the TNF family of cytokines (include TNF, lymphotoxin, CD40 ligand and 
CD27 ligand). Homologous areas within the TNF family are restricted to the 
carboxyl region (the extracellular domain which interacts with the receptor). The Fas 
ligand is more homologous to TNFa (27.8%), TNFp (28.7%) and LTp (which 
together with LTa represents lymphotoxins) than to ligands for CD40, CD27 and 
CD30. However, the FasL does not bind to the TNF receptor (Suda et al., 1993). 
The genes for murine FasL have been mapped to chromosome 1, and have been 
characterised from the rat (Suda et al., 1993) which showed a high degree of 
conservation between the two species. The proteolysis of membrane-bound TNF, 
which is mediated by a membrane-associated metalloproteinase, produces soluble 
TNF, (Gearing et al., 1994). The proteolysis by a metalloproteinase of membrane- 
bound FasL to the soluble form has been shown in human FasL (Kayagaki et al., 
1995). Since the CD40 ligand is also cleaved off from the membrane to become 
soluble, it is likely that all TNF cytokines are processed in the same way. It has been 
shown that the soluble form of human FasL exit as a trimer (Tanaka et al., 1997) but 
it is currently unknown whether the membrane form exists as a trimer. Soluble FasL 
has been detected in the serum of human patients suffering from large granular 
leukaemia of the T- or NK-type, as well as NK-lymphoma (Tanaka et al., 1996). The 
FasL is expressed in cytotoxic T-lymphocytes (CTL) and also natural killer cells 
though it has also been shown to be expressed in the immune privilege sites or the 
testis and the eye.
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1.8.3 The Fas Receptor and Ligand Interaction
Binding of the Fas receptor by the FasL involves trimérisation and initiates an 
apoptotic signal (Nagata and Golstein, 1995) which results in cell death. The same 
interaction has been shown by cross-linking Fas with agonistic antibodies (IgM class 
anti-APO antibody, or IgG3 class anti-Fas antibody) which induce apoptosis in cells 
expressing the Fas antigen (Trauth et al., 1989; Yonehara et al., 1989; Itoh et al., 
1991). Dimérisation of the receptor is insufficient to induce the apoptotic signal, 
though the IgM class antibody or the IgG3 class anti-APO 1 antibody are able to 
aggregate and thus function as agonists. It has been shown that the Fas cytoplasmic 
region binds to a molecule called F ADD (Fas-associated protein with death domain) 
or MORTl, which contains a death domain at its C terminus (Boldin et al., 1995; 
Chinnaiyan et al., 1995), through the death domain (Kischkel et al., 1995). The N- 
terminal region (known as the death effector domain (DBD)) is responsible for 
downstream signal transduction. It has been shown that TNFRl has a similar death 
domain-containing protein partner called TRADD (TNFRl-associated death domain- 
containing protein) (Hsu et al., 1995). Hsu et al. (1996a) showed that TRADD binds 
to FADD/MORTl via interactions between their death domains which suggests that 
Fas and TNFRl share a common signalling pathway downstream of FADD/MORTl. 
However, it has been shown that TNFRl has another pathway via RIP (receptor 
interacting protein) which though originally identified as a Fas binding protein, 
preferentially binds to TRADD (Hsu et al., 1996b). RIP is a serine/threonine kinase 
that contains the death domain motif and binds to TRADD via the death domains. 
The death domain of RIP is responsible for the signal transduction and not the kinase 
domain, which implies that RIP does not possess a death effector domain.
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Two separate groups identified the same molecule which bound to FADD/MORTl, 
which was originally called FLICE (FADD like ICE) or MACH (MORTl-associated 
Ced-3 homologue) (Muzio et al., 1996; Boldin et al., 1996) and is now termed 
caspase-8 (Alnemri et al., 1996). Caspase-8 has two DED motifs at the N-terminus, 
through which it interacts with FADD/MORTl and has been shown to be activated 
through this association with what has been termed as the death-inducing signalling 
complex (DISC) (Medema et al., 1997b). This activation has been shown to lead to 
proteolysis of other caspases, though more specifically caspase-3 like caspases, and 
thus the initiations of a caspase cascade (Boldin et al., 1996). However, it has not 
been determined exactly how caspase-8 is activated, though a possibility may be by 
autoproteolysis, though by what mechanism or how this is regulated is still unknown. 
Death adapter molecules, such as RAJDD (receptor-interacting protein (RIP)- 
associated ICH-1/CED-3-homologous protein with a death domain)/CRADD 
(caspase and RIP adapter with death domain), link FADD with TNFR and couples 
the complex to caspase-2 (Duan and Dixit, 1997; Chou et al., 1998). Tumour 
necrosis factor receptor-associated factor-2 (TRAF-2) has been shown to directly 
interact with TRADD (Hsu et al., 1996a) and hence a regulator of NF-kappa B 
activation.
Fas-associated phosphatase (FAP)-l is a tyrosine phosphatase which has been shown 
to interact with the 15 C-terminal amino acids of the Fas receptor (Sato et al., 1995). 
FAP-1 has been associated with resistance to Fas-mediated apoptosis owing to its 
ability to act as a negative regulatory domain (Itoh and Nagata, 1993). Another 
dominant-negative inhibitor of Fas-induced apoptosis is Daxx, a signalling protein 
that binds to the Fas death domain (Yang et al., 1997). Activation of Daxx leads to
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downstream activation of the Jun NH2-terminal kinase (JNK) pathway via the JNK 
kinase kinase, ASK-1 (Chang et al., 1998), thus completing a signal cascade from the 
Fas death receptor to kinase cascades that modulate nuclear transcription factors. The 
currently understood signalling cascade is shown in Fig. 6.
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pro-caspase-3
caspase-8
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Figure 6: The proposed scheme for the conventional FasR signaling pathway.
This pathway requires recruitment o f the adapter protein FADD to the oligomerized FasR. The 
recruitment o f FADD to FasR occurs as an interaction between the death domains o f the respective 
proteins. The death effector domain o f FADD in turn recruits the caspase-8 to the complex facilitating 
cleavage and activation o f caspase-8. Active caspase-8 then activates several effector caspases. This 
pathway also highlights the interaction between FasR and TNFR via the adapter proteins.
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1.8.4 Fas Function and Dysfunction
The FasR/FasL system plays a major physiological role, which has been confirmed 
by mutations. Mice homozygous for Ipr (lymphoproliferation) and gld (generalised 
lymphoproliferative disease) develop lymphoadenopathy, splenomegaly due to 
accumulating CD4", CDS' cells of T cell origin, and autoimmune disorders (Nagata 
and Suda, 1995). The Fas knockout mice generated by gene-targeting (Adachi et al., 
1995) showed more pronounced lymphoadenopathy and splenomegaly. When Fas 
was expressed in the lymphocytes of Ipr mice as a transgene, the lymphoproliferative 
phenotype was rescued (Wu et al., 1994) thus confirming that the Fas system plays a 
role in the programmed cell death of T lymphocytes.
1.8.4.1 Lymphocyte Development
The T-cell lymphocytes, which are responsible for the removal of potentially 
dangerous virally infected or cancerous cells, mature in the thymus. Immature T- 
cells enter the gland where they express their T-cell receptors (TCR) in conjunction 
with cluster differentiation factors CD4 and CDS. Most immature T-cells are useless 
or potentially dangerous to the organism, so it is vital that there is control to prevent 
autoimmune disorders. More than 95% of thymocytes that enter the thymus are 
deleted by negative or positive selection during their development. Thus thymocytes 
which express antigens that recognise self antigens or do not recognise the major 
histocompatibility complexes (MHC) are eliminated. In the periphery, mature T-cells 
that recognise receptors are also deleted by peripheral clonal deletion. Mature T-cells 
are activated to proliferate when they encounter target cells, but on completion of 
their task, they must be removed to prevent accumulation and possible autoimmune
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disorders. It has been shown by Nagata and Goldstein (1995) that the Fas system is 
involved in activation suicide of T-cells and thus the down-regulation of the immune 
system. This was seen by the accumulation of activated mature T-cells in Ipr and gld 
mice. Also, it has been postulated that peripheral clonal deletion may be Fas- 
mediated, though thymic clonal deletion has been shown to be normal in Ipr, gld and 
Fas knockout mice (Singer and Abbas 1994). These results suggest that the Fas 
system is not involved in the deletion process in the thymus, though this has still not 
been shown explicitly.
B-cells have also been shown to be regulated by the Fas system, by the accumulation 
of B-cells in Fas knockout mice (Cohen and Eisenberg, 1991). Deletion of B-cells 
recognising autoantigens occurs in the bone marrow, lymph glands and the spleen. 
The immunisation of mice with antigens rapidly induces Fas expression in germinal 
centres, and the activation of naive B-cells via CD40 makes them more susceptible to 
Fas-mediated cell death. However, even though FasL expressing T-cells kill the Fas- 
expressing activated B-cells, the exact role of Fas in the deletion of B-cells remains to 
be elucidated. Human mutations in the Fas receptor have been shown which shows 
that there is no peripheral clonal deletion of T-cells which leads to a similar 
phenotype (splenomegaly and lymphoproliferative disorders) which is seen in Ipr 
mice (Fisher et al., 1995). Some patients show autoimmune disorders such as 
haemolytic anaemia, thrombocytopenia and neutropenia by the production of 
autoantibodies against red blood cells and platelets. Another disorder of the Fas 
system in humans is that of human systemic lupus erythematosus (HSLE) which is a 
condition characterised by polyclonal B-cell activation and the production of 
autoantibodies. It has been shown that there is no consistent defect in the expression
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or function of the Fas receptor in the B-cells or T-cells of HSLE patients, though both 
cell types had elevated levels of the Fas receptor (Mysler et al., 1994). However, 
patients with autoimmune lymphoproliferative syndrome (ALPS) have defective Fas- 
mediated T-lymphocyte apoptosis as a result of deleterious mutation of the human 
Fas gene (APTl) (Fisher et al., 1995).
1.8.4.2 Cytotoxicity
The FasL as stated earlier is expressed on cytotoxic T lymphocytes (CTLs) which 
recognise and kill virally or bacteria infected cells. Likewise, FasL is found in 
natural killer (NK) cells, which kill cancerous cells, thus suggesting that Fas is 
involved in T lymphocyte mediated cytotoxicity. The previously studied mechanism 
for inducing cytotoxic cell death was the perforin/granzyme pathway but further 
studies showed that FasL was needed (Nagata and Golstein, 1995). Activation of 
CTLs through TCR interaction with viral antigens induces the expression of the FasL 
gene. The FasL expressed by the CTL then binds to the receptor on the target cell 
thus inducing the apoptotic signal. The perforin/granzyme system is triggered in the 
same way, with perforin punching holes in the target cell plasma membrane, through 
which the serine protease, granzyme B can pass. It has been shown that granzyme B 
induces apoptosis via a caspase dependent pathway by direct activation of effector 
caspases (Shi et al., 1996; Martin et al., 1996; Medema et al., 1997a).
1.9 The Liver and the Fas system
Work on Fas has generally focused on the cells of the immune system, yet the 
FasR/FasL system plays an important role in the pathogenesis of thyroiditis 
(Giordano et al., 1997), diabetes (Chervonsky et al., 1997), AIDS (Hiromatsu et al..
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1994), lymphomas (Fisher et ah, 1995) and fulminant hepatitis (Ogasawara et ah, 
1993; Galle et ah, 1995; Kondo et ah, 1997). Little is still known about how 
apoptosis is controlled in many of the latter organs. Hepatocytes or hepatoma cells 
may be induced to undergo apoptosis by cholestatic bile acids (Kwo et ah, 1996), 
topoisomerase I inhibitors (Adjei et ah, 1996), transforming growth factor p (TGFP) 
(Oberhammer et ah, 1992) and TNFa (Shinagawa et ah, 1991). Hepatocytes under 
normal conditions are subjected to an enormous metabolic demand owing to the 
nature of their physiological role. The liver is the site of xenobiotic metabolism as 
well as glycogen storage and has 75% of its blood flow derived from the digestive 
organs. Owing to the potentially damaging metabolites that are generated, damage to 
the liver can occur. Other potentially harmful toxins are xenomorphs such as viruses 
and parasites. Apoptosis occurs on tissue remodelling, such as the reversal of drug 
induced hepatomegaly, virally-, cytokine- or lymphocyte-induced hepatitis and drug- 
induced toxicity. As the organ plays a major role in the organism, dysfunction leads 
to a whole myriad of metabolic events, leading to plasma toxification, 
encephalopathies and eventually multiorgan failure.
Hepatocytes express high levels of Fas, which has been shown in vivo by 
intraperitoneal injection of anti-Fas antibody in mice to result in the death of the 
animals through fulminant hepatitis like massive liver damage (Ogasawara et al., 
1993). A similar phenotype was shown by the injection of the bacterial super antigen 
concavalin A (Leist et al., 1996), which through T-lymphocyte activation induced 
hepatic death. Lymphocytic infiltration and apoptosis have both been suggested to 
mediate the destruction of hepatocytes and also possibly biliary epithelium in various 
hepatobiliary disorders (Mizuhara et al., 1994). There is an upregulation of the Fas
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receptor, especially in the periportal area, in the liver in patients with chronic virally 
induced hepatitis (Samanta et ah, 1997). Mice with targeted mutations in the Fas 
gene showed substantial liver hyperplasia, which was accompanied by the 
enlargement of nuclei in hepatocytes (Adachi et ah, 1995). This was also seen in 
humans showing mutations in the Fas gene. Thus, the Fas system seems to play a 
role in the apoptotic process to maintain homeostasis of the liver. Though much 
work has been undertaken into Fas-mediated liver damage, the signalling cascade 
induced by Fas in hepatocytes remains unclear.
Previous studies carried out in primary hepatocyte cultures have shown that Fas- 
induced apoptosis may occur in vitro (Galle et ah, 1995; Ni et al., 1994; Rouquet et 
al., 1996a; Nishimura et ah, 1997. However, cultured cells are very refractory to 
anti-Fas antibody treatment as compared to the in vivo situation where full 
destruction of the liver occurs within a few hours. Experimentally, the development 
of tools such as the anti-Fas antibodies and rapid cell quantification will continue to 
be invaluable. With this, the nature of the Fas and death machinery could be 
unveiled. Full understanding of the Fas system is likely to prove invaluable in 
providing insights into various human autoimmune diseases as well as Fas-mediated 
liver disorders. Kass and Jones discuss the various methods used to study apoptosis 
in detail in the book chapter Methods for Assessing Apoptosis (Kass and Jones,
1999).
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1.10 Research Objectives
The FasR/FasL system has been implicated in the pathogenesis of various hepatic 
disorders including fulminant hepatitis. Investigating the Fas system in hepatocytes 
is of great importance in furthering the understanding of the role of Fas in liver 
disease, which has wide reaching medical implications. Various models have been 
used to study this though they have involved primary hepatocyte cultures, which do 
not represent a true depiction of events occurring in vivo.
The general aim of this project was to establish a system that could be used to 
investigate the mechanism of FasR-mediated apoptosis in murine hepatocytes and 
then use this to dissect out the role of intracellular mediators in the Fas signalling 
cascade. I used the isolated murine hepatocytes cultured in cell suspension system 
which responded to stimulation in the same way as in vivo following intraperitoneal 
injection of anti-Fas antibody in mice. This system would then be used to study the 
role of specific proteases and their substrates, which have been implicated in the Fas 
death machinery and to assess the involvement of other mediators such as specific 
kinases in the signalling cascade. Specifically, this general research approach will be 
pursued by undertaking the following research aims:
1. To develop a reliable system to investigate the mechanism of FasR-mediated 
apoptosis in isolated murine hepatocytes.
2. To assess the differences between hepatocytes in cell culture and cell suspension 
in response to Fas stimulation and to see how this is modulated with protein 
synthesis and kinase inhibitors.
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3. To examine the role of caspases and proteases in the death response induced 
through Fas using isolated murine hepatocytes in cell suspension. Various 
protease and caspase inhibitors would be used to assess the role of their relevant 
enzymes.
4. To determine the reasoning for the lack of PARP cleavage in FasR-mediated 
apoptosis in isolated murine hepatocytes. This would involve the optimisation of 
a cell-free system utilising isolated nuclei and cell extracts.
5. To investigate intrinsic mechanism of the Fas-induced death pathway.
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Chapter 2
Materials and Methods
38
2.1 Materials
Reagents used in this study are listed according to suppliers
Alexis, Ltd., UK 
Wortmannin, PD089059.
Amersham International pic, Buckinghamshire, UK
ECL detection reagents, conjugated sheep anti-mouse IgG-horseradish peroxidase 
antibody, protein molecular weight marker (biotinylated), streptavidin-peroxidase 
conjugate, Hybond C nitro-cellulose membrane, sodium dodecyl sulphate.
Bachem, Saffron Walden, UK
Z-Asp-2 ,6 -dichlorobenzoyloxymethylketone (Z-D-CK), A-acetyl-Asp-Glu-Val-Asp 
aldehyde (Ac-DEVD-CHO), A-acetyl-Asp-Glu-Val-Asp-chloromethylketone (Ac- 
DEVD-CMK), Z-Val-Ala-DZ-Asp-chloromethylketone (Z-VAD-CMK), Z-Val-Ala- 
DZ-Asp-fluoro-methylketone (Z-VAD-FMK) Ac-Tyr-V al-Ala-Asp-chloro- 
methylketone (Ac-YVAD-CMK), RGD peptide.
Bio-Rad Laboratories Ltd, UK
Glycine, protein molecular weight markers (high range), Whatmann 3MM filter 
paper, ammonium persulphate, acrylamide stock solution (30%), N, N, N, N- 
tetramethylethylenediamine (TEMED).
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Boehringer Mannheim Ltd, Mannheim, Germany
Collagenase H, albumin fraction V, A-Acetyl-Leu-Leu-norleucinal (calpain inhibitor 
I), A-Acetyl-Leu-Leu-methioninal (calpain inhibitor II), albumin faction V (BSA), 
[ethylenebis(oxyethylenitrilo)]-tetraacetic acid (EGTA), HEPES, phenyl- 
methylsulfonylfluoride (PMSF), Tris, and trans-epoxysuccinyl-L-leucylamido-(4- 
guanidino)butane (E-64), low melting point (LMP) agarose, field inversion gel 
electrophoresis (FIGE) y DNA markers.
British Drug House (BDH) Ltd, UK
2 -p-mercaptoethanol, cupric sulphate (CUSO4), disodium hydrogen phosphate 
(Na2HP0 4 ), ethylendiaminetetraacetic acid (EDTA), glycine, magnesium chloride 
(MgClz), potassium chloride (NaCl), potassium dihydrogen phosphate (KH2PO4), 
potassium sodium tartrate, sodium chloride (NaCl), sodium hydrogen carbonate 
(NaHCOs), trichoroacetic acid (TCA), polyoxyethelenesorbitan (Tween-20), boric 
acid.
Calbiochem-Novabiochem (UK) Ltd, UK
Dimethyl sulphoxide (DMSO), nonidet P-40 (NP-40), A-tosyl-Z-phenylalanine 
chloromethyl ketone (TPCK), A-tosyl-Z-lysine chloromethyl ketone (TLCK), 
Hoechst 33342, thapsigargin, 3,4-dichloroisocoumarin (DCI), benzyloxycarbonyl- 
Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin (Z-DEVD-AFC) and Z-Tyr- 
V al-Ala-Asp-7-amino-4-trifluoromethylcoumarin (Z-YVAD-AFC).
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Fischer Scientific International Co., UK
Methanol, ethanol (96%), potassium acetate, sodium hydroxide (NaOH), 
hydrochloric acid (HCl), acetic acid (glacial), formaldehyde.
Gibco-BRL, Paisley, Scotland 
Ultra-pure agarose. 
Pharmacia Biotech, UK
Commassie brilliant blue (R250), agarose NA.
PharMingen, San Diego, CA 
Hamster anti-mouse anti-Fas antibody (Jo2).
Promega Corporation, UK 
X DNA EcoRl Hind El markers, DNA loading buffer.
Sigma-Aldrich Chemical Co. Ltd, UK
Phorbol 12-myristate 13-acetate, proteinase K, RNase A, amino-4- 
trifluoromethylcoumarin (AFC), p-glycerophosphate, ponceau S, pyronin Y, urea, 
lauryl sarcosine, pronase, ethidium bromide, bromophenol blue, dexamethasone, 
Folin-Ciocalteau phenol reagent, glycerol, tiypan blue (0.4%), Tris base, adenosine 
triphosphate (ATP), creatine phosphate, creatine kinase, cyclohexide from 
streptomyces griseus, poly-L-lysine (hydrobromide, y-irradiated) Mw 70,000-150,000, 
epidermal growth factor.
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Anti-poly (ADP-ribose) polymerase (PARP) monoclonal antibody clone C-2-10 and 
bovine thymic PARP which was partially purified by affinity chromatography up to 
DNA cellulose step were gifts fi*om Dr. Guy G. Poirier (Laval University, Quebec, 
Canada) and generated as described by Shah et al. (1995). Anti-caspase-3 antibody 
and recombinant human caspase-3 were kindly provided by Dr. Don Nicholson 
(Merck Frosst Centre for Therapeutic Research, Quebec, Canada) and anti-caspase-7 
was fi*om Dr. Gerald Cohen (MRC Toxicology Unit, Leicester, England).
2.2 Solutions and Buffers
2.2.1 General
Phosphate buffered saline (PBS), pH  7.4
11.5 g di-sodium hydrogen orthophosphate, anhydrous
2.96 g sodium dihydrogen orthophosphate 
5.84 g sodium chloride 
Made up to IL with Milli-Q water and the pH adjusted to 7.4. Stored at 2-8°C
Tris-buffered saline (TBS), pH  7.4 
2.42 g Tris base
8 . 0  g sodium chloride 
Made up to 1 L and pH adjusted to 7.4 with HCl. Stored at 4 °C
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2.2.2 Agarose Gel Electrophoresis
lOx TBE (per litre) fo r  low molecular DNA analysis 
890 mM Tris base 108.0 g
890 mM boric acid 55.0 g
25 mM EDTA (Mw 372) 9.3 g
Autoclaved and stored at +4°C.
lOx TBE (per litre) fo r  high molecular weight DNA analysis 
890 mM Tris base 108.0 g
890 mM boric acid 55.0 g
250 mM EDTA (Mw 372) 93 g
Autoclaved and stored at +4°C.
Ix TBE (per litre)
100 mis lOx TBE 
900 mis Milli-Q water
0.5x TBE (5 litres), pH  8.5 (adjust with conc. HCl)
250 mis lOx TBE 
4,750 mis Milli-Q water
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NDS buffer (per 500 ml)
1% lauryl sarcosine buffer 5.0 g
0.5 mM EDTA (Mw 372) 93.0 g
10 mM Tris base 0.605 g
pH 8.0
EDTA and Tris base were dissolved in 350 ml of Milli-Q water and 10-12 grams of
NaOH pellets were added bringing the pH to 8.0. 5 grams of lauryl sarcosine was
dissolved in 50 mis of Milli-Q water and then added to the EDTA and Tris solution.
The pH was adjusted to 9.5 with NaOH, made up to 500 ml, filtered and stored at
4°C.
TE8 buffer (per litre)
10 mM Tris base 10 ml (1 M stock)
1 mM EDTA (Mw 372) 10 ml (100 mM stock)
pH 8.0
DNA standard buffer (per 100 ml)
0 . 0 1  % lauryl sarcosine buffer 0 . 0 1  g
50 mM EDTA (Mw 372) 50 ml (100 mM stock)
10 mM Tris HCl 10 ml (1 M stock)
Milli-Q water 40 ml
5 pg /ml proteinase K 0.5 mg
pH 8.0
Filter sterilised (0.2 mm) and stored at 4°C.
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Ethidium Bromide (carcinogen)
5 mg/ml Milli-Q water
Pronase (20 mg/ml)
120 mg was dissolved in 6  mis of Milli-Q water and stored at-20°C in 600 pi aliquots
Proteinase K  (25 mg/ml)
150 mg was dissolved in 6  mis of Milli-Q water and stored at-20°C in 500 pi
aliquots.
RNase A (50 mg/ml)
50 mg was dissolved in 1 ml of 10 mM Tris HCl (pH 7.5) containing 15 mM NaCl.
This was then boiled for 15 min. at 95°C and stored at -20°C in 100 pi aliquots
2.2.3 Primary Hepatocyte Isolation and Culture
Krebs-Hens eleit Buffer (2x stock solution)
Adding the following stock solutions made up this solution 
200 ml NaCl solution (16.09% % )
150 ml KCl solution (1.10% % )
25 ml KH2PO4 solution (0.22 M)
50 ml MgS0 4  solution (0.11 M)
50 ml CaCL solution (0 . 1 2  M)
835 ml Milli-Q water
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The solution was gassed with carbogen (95% 0 2 :5 % CO2), prior to the addition of 1
L of NaHCOs (0.971% % ) solution. The solution was then stored at 4°C in the dark.
lOx Hank Buffered Salt Solution (per litre)
Combining the following compounds made this solution:
80 g NaCl 
4 g KCl 
2.16 gMgS04 
0 . 6  g Na2HP04 
0.6 g K H 2 P O 4
The reagents were dissolved in Milli-Q water and stored at 4°C.
Cell Preparation Solutions
Ix Hank Buffer (prepared fresh)
Made by combining the following:
25 ml lOx Hank stock 
525 mgNaHCO]
225 ml Milli-Q water 
745 mg Hepes
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Pre-collagenase perfusion buffer (prepared fresh)
Made by combining the following:
150 ml Ix Hank Buffer solution 
30 mg EGTA
1.0 g BSA
The pH was adjusted to 7.4 with NaOH and then pregassed with carbogen prior to 
use.
Collagenase Perfusion Buffer (prepared fresh)
Made by combining the following:
100 ml Ix Hank Buffer solution 
30 mg CaCb 
200 mg BSA 
50 mg colleganase H
The pH was adjusted to 7.45 with NaOH and then filtered if particulates were 
present. The solution was pregassed with carbogen prior to use.
Cell Suspension Buffer (prepared fresh)
50 ml 2x Krebs-Hensleit Buffer stock 
50 ml Milli-Q water 
238 mg Hepes
1.0 g BSA
The pH was adjusted to 7.4 with NaOH and the solution was pregassed with carbogen 
prior to use.
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2.2.4 SDS-PAGE and Western Blotting
0.5M Tris-HCl, pH  6.8
6.0 g Tris base
Made up to a final volume of 100 ml after adjusting pH to 6 . 8  with HCl and stored at 
2-8°C
Resolving gel buffer 2X  
181.1 g Tris base
Dissolved in approximately 900 ml of Milli-Q water. Then the pH was adjusted to
8 . 8  with HCl and then made up to a final volume of IL. This was stored at 2-8°C.
Stacking gel buffer (2x stock solution)
60.6 of Tris base
The above reagents were dissolved in 900 ml of Milli-Q water and the pH was 
adjusted to 6 . 8  with HCl. The solution was made up to IL and stored at 2-8°C.
Ammonium persulphate stock solution (10% w/v)
1.5 g ammonium persulphate
15.0 ml Milli-Q water
The reagents were mixed well and stored in 400 pi aliquots at -20°C.
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Resolving gel (7%) (enough fo r  2 gels: sets quickly)
4.00 ml acrylamide stock solution (30 % w/v)
4.00 ml resolving gel buffer (2x)
7.96 ml Milli-Q water
80 pi 20% SDS
80 pi ammonium persulphate stock solution (1 0 % w/v) 
8  pi N, N, N, N-tetramethylethylenediamine (TEMED) 
The solution was mixed well prior to use.
Resolving gel (13%)
6.70 ml acrylamide stock solution (30 % w/v)
4.00 ml resolving gel buffer (2x)
5.2 ml Milli-Q water
80 pi 20% SDS
80 pi ammonium persulphate stock solution (1 0 % w/v) 
8  pi N, N, N, N-tetramethylethylenediamine (TEMED) 
The solution was mixed well prior to use.
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Stacking gel (4%) (enough for 2 gels: sets quickly)
1.5 ml acrylamide stock
2.5 ml stacking gel buffer (2x)
6.0 ml Milli-Q water
50 pi 20% SDS
40 pi ammonium persulphate stock solution (10 % w/v)
20 pi N, N, N, N-tetramethylethylenediamine (TEMED)
The solution was mixed well prior to use.
TBS-Tween (TBS-T), pH  7.4
The required volume of Tween-20 was dissolved in Ix TBS to give a 0.1% solution
i.e. 800 ml TBS with 0.8 ml of Tween-20. This was stored at 2-8°C and the pH was 
checked prior to use.
Loading buffer (2x stock)
4.8 ml Milli-Q water
1.2 ml Tris-HCl (0.5 M stock, pH, 6 .8 )
0.96 ml glycerol
1.92 ml SDS (10% %  stock)
0.48 ml p-mercaptoethanol 
0.6 ml 0.05% (w/v) pyronin Y 
This was stored in dark at room temperature for a max of 2 weeks.
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Reducing Loading buffer
4.8 ml Milli-Q water
1.2 ml Tris-HCl (0.5 M stock, pH, 6 .8 )
0.96 ml glycerol
1.92 ml SDS (10% %  stock)
0.48 ml P-mercaptoethanol 
0.6 ml 0.05% (w/v) pyronin Y 
3.58 g urea
This was stored in dark at room temperature for a max of 2 weeks.
Ponceau S (membrane staining dye)
0.1 mg ponceau S 
5 ml acetic acid (glacial)
Made up to 100 ml in Milli-Q water and stored at room temperature.
5Xrunning buffer
30.0 g Tris base
144.0 g glycine
Made up to 2 L and stored at 2-8 °C. Prior to use, 200 ml was diluted in I L final 
volume of Milli-Q water and SDS was added to a final concentration of 0.1% i.e. 5 
ml 20% SDS in IL of Ix running buffer. The pH was checked and adjusted to 8.3
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Transfer buffer
3.025 g Tris base 
14.41 g glycine 
2 0 0  ml methanol
Made up to IL in Milli-Q water and stored at 2-8 °C (could be reused 2-3 times)
Membrane blocking solution
Prepared by adding 5 g of fat-free milk powder to 100 ml of TBS-T solution.
Commassie stain
This was made by the addition of 25 ml of commassie brilliant blue solution (1% %
aqueous stock), to a mixture of 45 ml of methanol, 10 ml glacial acetic acid and 20
ml of Milli-Q water.
Destaining buffer
Made by mixing 45 ml methanol, 10 ml acetic acid in 45 ml of Milli-Q water.
2.2.5 Cell-Free System
Mouse Liver nuclei isolation
Made by adding the following stock solutions:
10 ml Tris-HCl solution (500 mM stock, pH 7.5)
2.5 ml KCl solution (IM stock)
1 ml MgCl2 (500 mM stock)
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The buffer was made up to 100 ml in Milli-Q water and then pH adjusted to 7.5 using 
HCl. This was stored at 4°C.
Homogenisation buffer
The following solutions made up this buffer:
1 ml MgCli (500 mM stock)
2 ml Tris-HCl (10 mM stock, pH 7.5)
180 g sucrose
The above solutions were combined and made up to 100 ml in Milli-Q water ensuring 
that the pH was adjusted to 7.5. This was stored at 4°C.
Centrifugation buffer
Combining the following stock solutions made up this buffer:
10 ml Tris-HCl solution (500 mM stock, pH 7.5)
2.5 ml KCl solution (IM stock)
1 ml MgCb (500 mM stock)
50 ml Sucrose (4.6 M stock)
The buffer was made up to 100 ml in Milli-Q water and then the pH was adjusted to
7.5 using HCl. This was stored at 4°C.
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Buffer A
Made by adding the following stock solutions;
2 ml Tris-HCl solution (500 mM stock, pH 7.5)
0.25 ml KCl solution (IM stock)
0.5 ml MgCb (500 mM stock)
22.8 ml sucrose (2.2 M stock)
The buffer was made up to 100 ml in Milli-Q water and then the pH was adjusted to
7.5 using HCl. This was stored at 4°C.
Rat thymocyte Nuclei solutions 
Buffer B
Made by combining the following solutions:
5 ml Tris-HCl solution (200 mM stock, pH 7.5)
0.3 ml MgCl] (500 mM stock)
1 ml KCl solution (1 M stock)
0.1 ml NP-40 (warmed up prior to addition)
The buffer was pH adjusted to 7.9 using HCl and then stored at 4°C.
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Thymocyte and hepatocyte Cell extract solutions 
Cell lysis buffer
Combining the following compounds made up this buffer:
864 mg p-glycerophosphate
292.2 mg NaCl 
152.14 mg EGTA
238.3 mg Hepes
The buffer was made up to 100 ml in Milli-Q water and then the pH was adjusted to
7.0 using NaOH. This was stored at 4°C.
ATP-regenerating stock (20x stock)
24 mg ATP
65.4 mg creatine phosphate 
1 mg creatine kinase
All the reagents were weighed into separate eppendorf tubes and solubilised in 1 ml 
of cell lysis buffer. The solution was then stored in 10 pi aliquots in 0.5 ml tubes at - 
20°C.
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2.2.6 Caspase activity solutions
Caspase activity assay buffer
Made up fresh each time by the following:
2.383 g Hepes 
1 0  g sucrose
0.1 ml NP-40 (warmed prior to use)
154 mg DTT
The compounds were dissolved in 100 ml of Milli-Q water and the pH was adjusted 
to 7.4 with NaOH.
2.3 Animals
Male Balb/C mice were purchased from Bantin & Kingman (UK) at a weight of 25 g 
(6 - 8  weeks old) as well as male Wistar rats (75-85 g), and fed ad libitum on standard 
powdered meal in a controlled environment (21-24 °C, 30-40% humidity and an 
alternating 1 2  hour cycle of light and dark).
2.4 Cell lines
The human leukemia T-cell line, Jurkat (clone E6-1) was obtained from ATCC and 
the murine T-cell hybridoma, Do-11-10 was from ECACC. Both cell lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum and were used 
as positive controls for the detection by Western blot analysis of caspases-3 and -7 
processing and poly (ADP-ribose) polymerase (PARP) cleavage during apoptosis.
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2.5 Isolation of Mouse Hepatocytes
Hepatocytes were isolated by a retrograde, non-recirculating in situ collagenase 
perfusion of livers from male Balb/c mice by a modified procedure from Moldéus et 
al., (1978). This method uses canulation and perfusion {in situ) via the abdominal 
section of the inferior vena cava, with perfusate efflux through the cut hepatic portal
vein.
Pre-collagenase, collagenase, and cell suspension buffers together with PBS solutions 
were prepared by warming to 37°C and carbogen gassing for 5 minutes. The animal 
was anaesthetised by inter-peritoneal injection of 1 2 0  mg/kg body weight of sodium 
pentobarbitone, and then secured on a grid platform above a large glass petri-dish. 
The skin was swabbed with 70% ethanol, then the abdominal cavity was opened and 
the viscera was deflected to the right. A loose ligature was placed around the upper 
section of the exposed inferior vena cava, and the vessel cannulated and ligated with 
a 22 gauge Teflon cannula, towards the liver entering the vessel above the renal vein 
branches. Any air bubbles present in the perfusate was dispelled prior to 
cannulations. The cannula was connected to perfusion silicon tubing primed with 
pre-collagenase perfusate flowing at 2.5 ml/min via a peristaltic pump. The liver was 
allowed to swell briefly (to aid tissue disruption) prior to severing of the portal vein. 
The thoracic cavity was opened and the thoracic vena cava and aorta clamped shut to 
ensure maximum perfusion delivery to the liver, whilst the pre-collagenase buffer 
was allowed to perfuse for 5 minutes. Following pre-collagenase buffer perfusion, 
the peristaltic pump was temporarily switched off whilst the perfusate reservoir was 
changed to the collagenase buffer, ensuring that there was no mixing of the solutions. 
The pump was then switched on and the collagenase buffer allowed to perfuse for 10
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minutes, during which time the gall bladder was carefully dissected out. A soft, 
swollen, healthy looking liver not exhibiting white necrotic patched indicated a good 
preparation.
The perfused liver was transferred into a sterile shallow petri-dish containing PBS 
(pre-warmed to 37°C and gassed with carbogen for 5 minutes). Livers were held 
with forceps and gently disrupted with other forceps. The hepatocytes were dispersed 
by gentle stirring motions. The resultant suspension was then filtered through gauze 
and made up to 100 ml with PBS in a sterile 50 ml centrifuge tube.
2.6 Mouse Cell Suspension and Treatment
The cell suspension was centrifuged for 2 minutes at 80 g  twice, being resuspended in 
PBS between spins. The cells were then resuspended in 50 ml total of cell 
suspension buffer, and 2 ml aliquots placed in each of 10-12 incubation flasks. The 
incubation flasks were attached to a rotary evaporator by a glass spider, which was 
set to 60 rpm via a voltage regulator. The flasks were arranged in such a way that 
they were rotated through a regulated water bath set at 39°C (such that the cell 
suspension was 37°C). Carbogen gas was continuously flushed through the flask 
atmospheres. After being placed in the incubation flasks, the cells were allowed to 
recover for 30 minutes before centrifugation for 5 minutes at 80 g  in a final volume 
of 50 ml cell suspension buffer. This was to enable removal of necrotic cells (also 
disrupted cells) caused by the isolation procedure, and hence increase cell viability. 
With the method used, the cell viability at this stage was found to be greater than 
90%. The cells were resuspended at a concentration of 1.6 x 10  ^ cells/ml in cell 
suspension buffer, and 2  ml aliquots placed in each of the 1 0 - 1 2  incubation flasks.
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The hepatocyte suspension containing incubation flasks could each be removed, 
treated with different substances and replaced back onto the incubation apparatus. As 
such, effects could be observed at set time points.
Time-course and dose-response relationship studies were conducted using the 
apoptotic inducing hamster monoclonal IgG anti-Fas (mouse) antibody, Jo2, at 
varying concentrations between 10 and 500 ng/ml. Isolated hepatocytes incubated 
with sodium azide at a concentration of 0 .0 0 0 1 % (% ) were also examined in the 
incubation system as a control measure, due to its inclusion in the antibody reagents 
purchased (this control concentration equated to twice that included with the 
maximum amount of antibody used). The anti-Fas antibody was diluted in PBS (0-0.1 
mg/ml) prior to addition and stocks of the protease inhibitors (100 mM) were in 
dimethylsulfoxide, methanol or H2O. The final concentration of solvent in the cell 
incubation mixture never exceeded 0 .1 % (%) and no induction or suppression of 
apoptosis was observed.
2.7 Preparation of Plates for Primary Cultures
For primary cell culture, all work and preparation of reagents was undertaken in 
sterile conditions to minimise the potential of micro-organism infection as no 
antibiotics were used.
Poly-L-lysine was diluted in sterile Milli-Q water to a concentration of 0.5pg/ml and 
2 ml administered per well of 6  well Nunclon plates, and incubated for one hour at 
37°C in an atmosphere of 95% O2 : 5% CO2 in a humidified incubator. The 
supernatant was removed and the well washed with 2 ml of sterile Milli-Q water.
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The plates were then incubated for at least three hours under the same conditions 
prior to storing at 4°C. For the fluorescence microscopy work, the cover slips were 
prepared in the wells under the same conditions.
2.8 Primary Cell Culture of Hepatocytes and 
Treatment
The isolated hepatocytes were cultured on to poly-L-lysine coated 6  well tissue 
culture plates at a density of 0 . 6  x 1 0  ^cells/well for one hour in cell suspension buffer 
(final concentration of NaHCOs was 0.05M, pH stabilised at 7.52). Unattached cells 
were removed by aspiration and the attached cells were further incubated in 2  ml of 
fresh cell suspension buffer, prior to treatment with various chemicals. For direct 
comparative purposes, the freshly isolated cells were subdivided for cell culture or 
suspension with an hour interval prior to treatment. The cell concentation of 0.6x10^ 
cells/well was found to be optimal for viability and for visualisation.
For Hoechst 33342 staining, cells were prepared in the same way, except that they 
were grown on a cover slip prepared as described previously. For RGB peptide 
treatment, the cell culture was prepared in two different manners: the cells were place 
in the suspension system at 2 x 10  ^cell/ml for 30 minutes to stabilise, then cultured at 
0.6 X 10  ^ cells/well with the direct addition of the RGB peptide. Following 
incubation for 30 minutes the anti-Fas antibody was added.
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2.9 Assessment of Apoptosis
2.9.1 Morphological Analysis by Light Microscopy
During the course of incubation, two sets of samples were taken at set time-points, 
namely 30 minutes intervals. One sample set was diluted 2x with 0.4% trypan blue 
(% ) in PBS, and cells were microscopically examined for stain exclusion (viability). 
This tested the structural integrity of the plasma membrane so that necrotic cells stain 
an intense blue. Counting cell blebbing in conjunction with a haemocytometer 
assessed apoptosis. In brief, 200 viable cells were examined and those exhibiting 
apoptotic blebs were assigned as apoptotic.
In cell culture, apoptosis was initially assessed using trypan blue staining (lOOpl of 
0.4% trypan blue/well). Thus the apoptotic cells were assessed using morphological 
blebbing. Care was taken to distinguish between blebbing induced by apoptosis and 
the changes the cell undergoes on culturing. Also, care was taken to ensure that the 
planes of vision used were representative of the culture cells and not the necrotic cells 
found in the supernatant.
2.9.2 Morphological Analysis by Fluorescence Microscopy
For the analysis of changes in nuclear morphology, samples were fixed in 4% (%) 
formaldehyde at room temperature for 30 minutes. The fixed cells were resuspended 
in PBS containing Hoechst 33342 ( 6  pg/ml) for 10 minutes prior to visualisation 
using a Zeiss Axiovert fluorescence microscope. For assessing the culture cells, the 
cover slips in the wells were removed at the set time, the media aspirated off, and 1 
ml of 4% formaldehyde added. These could be stored for a few days at 4°C. The 
media was then removed by aspiration and then the cells stained as previously
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described. The nuclei were scored as either normal, in which the chromatin was 
uncondensed, or apoptotic, in which the chromatin was highly condensed, yielding a 
high blue fluorescence or fragmented into discrete apoptotic bodies. Isolated nuclei 
samples were analysed the same way but without prior fixation. The nuclei were 
scored as either normal, in which the chromatin was uncondensed, or apoptotic, in 
which the chromatin was highly condensed or fragmented into discrete apoptotic 
bodies.
2.9.3 Analysis of High Molecular Weight DNA fragments by FIGE
The analysis of HMW DNA fragments was performed essentially as previously 
described by Weis et al., (1995). In brief, at least 1x10^ cells from each treatment 
were collected and centrifuged at 170 g  for 5 minutes. The pellets were resuspended 
in 50 pi of prewarmed PBS (50°C) and incubated in a waterbath at 50°C for 10 
minutes prior to addition of 50 pi of 1% prewarmed LMP agarose. Then 100 pi of 
each cell sample was pippetted to the well of the insert mould forming sample plugs, 
which was then placed on ice. The sample plugs were then placed into 1 ml of NDS 
buffer in a multiwell plate, to which 50 pi of 20 mg/ml pronase was added and 
incubated at 50°C for 24 hours. The NDS buffer containing pronase was replaced 
with fresh solution and continued to incubate at 50°C for a further 24 hours. Fresh 
NDS buffer was added and stored at 4°C until required (stable for several years) 
when the sample plugs were washed 3 times in TE8  buffer , 1/4 -1/6 cut off and 
inserted into the well of a 1% agarose gel. The pulse controller was set to the 
required program, and the gel electrophoresed at 200 V for 7 hours. The gel was then 
washed in Milli-Q water and incubated in 200 ml TE8  containing 40 pi of 5 mg/ml 
ethidium bromide stock for 30 min, gently rocking. The gel was then washed several 
times with fresh TE8  prior to UV visualisation.
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Switcher Programming (Hoefer Switcher) for FIGE
Program 1:
Run in: 15 minutes.
Run time : 2 hours.
Pulse: 2.4 sec to 2.4 sec.
Mode: Rev. F /R  3:1
Program 2:
Run in: 0.00 minutes
Run time: 5 hours
Pulse: 2.4 sec to 24 sec.
Mode: Rev. F / R 3:1
The temperature of the buffer during run was kept at 4°C. The resolution was found 
to increase if  the temperature was kept constant with precooling the system to 4°C 
before running owing to the heat generation. The two programs were concatenated, 
with program 1 first followed by program 2 , both set as a single multi-program, and 
the voltage constant at 200 V.
2.9.4 Analysis of Low Molecular Weight DNA fragments by 
Agarose Electrophoresis
The analysis of LMW DNA fragments was essentially as previously described by 
Weis et al, (1995) with the following modification. Aliquots of the cell suspension 
containing 1x10^ cells were fixed in ice-cold ethanol [50% (%)] on ice and stored at 
-20°C. This was found to inhibit intrinsic DNase activity and enable samples to be 
stored for up to four weeks prior to analysis (Gong et al., 1994). Cell culture samples 
were prepared by adding 1 ml of 1 0 0 % ethanol to the media and the cells harvested
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using a tissue culture scraper. Following centrifugation at 170 g for 5 minutes, the 
cells were resuspended in 70% ethanol and could be stored at -20°C until required.
For analysis, the cells were pelleted by centrifugation at 170 g  for 5 minutes followed 
by washing in PBS, and then resuspended in 15 pi of PBS and mixed with 6  pi of 
RNase A (stock of 50 mg/ml). After 15 minutes incubation at room temperature, 30 
pi of DNA loading buffer was added and 20 pi aliquots from each sample was loaded 
into the wells of a 1 .8 % (% ) agarose separating gel of which the top was replaced by 
a 0.8% (% ) agarose digestion gel, containing 2% (%) SDS and 1.25 mg/ml of 
proteinase K. The gel was run overnight (17 hours) at lOV followed by 3 hours at 
70V prior to washing in Milli-Q water. The gel was then incubated, gently rocking, 
with TE8  buffer containing 2 mg/ml RNase A overnight. The gel was then stained 
with 0.5 pg/ml ethidium bromide prior to visualisation under UV illumination. For 
isolated nuclei, the analysis of oligonucleosomal length DNA fragmentation was 
performed essentially the same.
2.10 SDS-PAGE and Western Blotting
2.10.1 Sample preparation
For the analysis of caspase processing from their pro-forms to their catalytically 
active forms upon Fas activation, aliquots of the cell suspension were centrifuged, 
pelleted, resuspended in loading buffer and their proteins (30 pg/lane) were resolved 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 13% gels. For the 
analysis of PARP, the pellet was resuspended in a defined volume of reducing- 
loading buffer (100 x 10  ^cells/ml). Resuspension of cells in loading buffer could be 
done with a P I 0 0 0  pipette as the solution became veiy viscous due to lysis of cells
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and hence presence of DNA. To break the DNA, sonication on ice was done for 4 x 
5 seconds with a medium power. The samples were then ready and either kept at - 
20°C before analysis or directly incubated at 65°C prior to gel loading. All samples 
were kept in 15 pi aliquots and the protein concentration was determined using the 
Lowry method. In the cell free system, the total reaction mixture (30 pi) was 
resuspended in 50 pi of reducing-loading buffer and sonicated on ice for 20 seconds. 
The samples containing 1.2 x 10  ^nuclei or 40 ng of purified PARP were loaded onto 
the gel.
2.10.2 Polyacrylamide Gel Electrophoresis
The SDS-PAGE 13% or 7% gels were prepared using a Bio-Rad mini gel system. 
The stacking gel comprised a 4% concentration and the resolving gels where either 
13% for caspase processing or 7% for PARP processing, which offered the optimum 
separations. The gels were cast using the previously described recipes. The samples 
were loaded in 20 pi aliquots and electrophoresis was carried out for 60-70 minutes at 
120V until the loading dye was within 4 mm of the bottom of the gel.
2.10.3 Western Transfer of Proteins
Whatmann 3MM filter paper, Hybond C nitrocellulose membrane and scotchbrite 
pads were soaked in transfer buffer for 5-10 minutes. The transfer of proteins was 
carried out by layering two pieces of filter paper, followed by the gel, and then the 
nitrocellulose membrane. This was then layered by two more pieces of filter paper, 
sandwiched within the scotchbrite pads and then placed in the BioRad transfer 
system. The transfer tank was filled with pre-cooled transfer buffer after having 
placed the cooling element. The transfer was carried out overnight at 34 V (0.1 A) or
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at 60V (0.146 A) for 2 hours. Following transfer, the protein profile was checked on 
the membrane by staining with ponceau S solution for 1 minute, followed by 
destaining in analar water. The efficiency of transfer was determined by staining the 
gel in Commasie blue for about 1 hour, and de-staining for several hours or 
overnight.
2.10.4 Immunoblotting
The membranes were then blocked for 1 hour (TBS supplemented with 5% (% ) non­
fat powdered milk, 0.1% (%) Tween-20, pH 7.4) followed by probing with 
antibodies directed against caspase-3 (p i7 subunit) (1:1,000 dilution), caspase-7 (p i9 
subunit) (1:2,000 dilution) or PARP (1:10,000 dilution) in TBS containing 0.1% (%) 
Tween-20 and incubated overnight. After washing and incubation for 1 hour with the 
secondary antibody labeled with horseradish peroxidase the blot was visualized with 
the ECL detection system as described by the manufacturer (Amersham).
2.11 Cell Free System
2.11.1 Preparation of Cell Extracts
Cell extracts were prepared as previously described by Nicholson et al., (1995). To 
induce apoptosis in isolated hepatocytes, the cells were incubated with 1 0 0  ng/ml of 
anti-Fas antibody (Jo2) and in isolated thymocytes, the cells were incubated with 1 
pM dexamethasone. The cells were washed twice with PBS, pH 7.4 and resuspended 
( 1 0 0  X 1 0  ^ cells/ml for thymocytes, 1 0  x 1 0  ^ cells/ml for hepatocytes) in cell lysis 
buffer. After three cycles of freezing and thawing, the cell lysates were centrifuged at 
15,800 g- for 30 minutes and the supernatants retained. The protein concentration was 
determined using the Lowry protein assay.
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2.11.2 Measurement of Caspase Activation using Fluorogenic 
Substrate Peptides
Caspase activity was assayed at room temperature using a microtitre plate and a 
fluorimeter (WellFluor, Denley) in a reaction mixture containing 40 pM Z-YVAD- 
AFC or Z-DEVD-AFC, 0.24 mg cellular protein, in caspase activity assay buffer. 
This was performed in the absence or presence of 50 nM Ac-DEVD-CHO in a final 
volume of 200 pi. All experiments were undertaken with a linerised standard curves 
of AFC (0-50 pM) in assay buffer in a final volume of 200 pi which was within the 
range of the assays.
2.11.3 Isolation of thymocytes
This was carried out essentially as previously described (Chow et al., 1995). Male 
Wistar rats (75-85 g) or male Balb/c mice (25-30 g) were killed by an overdose 
administered by intra-peritoneal injection of 1 2 0  mg/kg body weight sodium 
pentobarbitone. The thymic glands were dissected out, removing the parathymie 
nodes and connective tissue. The thymic glands were carefully minced and disrupted 
in PBS. The crude cell suspensions was then filtered through gauze and then through 
a 2 ml syringe containing gauze to remove debris. The cells were centrifuged at 
1,250 rpm for 5 minutes and either processed for isolation of nuclei, or resuspended 
in cell suspension buffer (5x10^ cells/ml). The thymocytes were incubated in 20 ml 
culture flasks at 37°C in a atmosphere of 95% O2 : 5% CO2 in the presence of 1 pM 
dexamethasone or carrier solvent (DMSO, final concentration = 0.01%) for 4 hours.
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2.11.4 Isolation of Rat Thymocyte Nuclei
Rat thymocyte nuclei were prepared as previously described (Chow et al., 1995) from 
male Wistar rats (75-85 g) with some modifications. In brief, isolated thymocytes 
were pelleted at 1,250 rpm for 5 minutes and resuspended in buffer A, giving a final 
cell suspension of 250 x 10^/ml. This was then mixed with buffer B (containing 0.1% 
NP-40) to give about 50% cells stained positive with trypan blue. This step was 
carefully titrated, starting with 1:1 (%) mixing. Once a dilution giving about 50% 
cells stained with trypan blue was achieved, the mixing could be scaled up and the 
cell suspension was homogenised with a loose fitting glass teflon hand homogeniser 
(3 strokes) on ice. The cell suspension was then centrifuged at 900 g  for 5 minutes 
onto a 100 pi 2.1 M sucrose cushion (pH 7.0). The pellet was resuspended in 4 ml
0.5 M sucrose buffer, homogenised (3 strokes) and filtered through 3 layers of gauze. 
The filtrate was resuspended in 7 ml 2.1 M sucrose and then a 1ml layer of 2.5 M 
sucrose pippetted onto it. The final spin to isolate the nuclei pellet was performed at 
70,000 g  for 80 minutes at 4°C and the nuclei were suspended in buffer A at a final 
concentration of 4-5 x 10  ^nuclei/ml. The nuclei were stored at -70°C until used.
2.11.5 Isolation of Mouse Liver Nuclei
Mouse liver nuclei were prepared by a procedure modified from Rickwood et al., 
(1997). Male Balb/c mice (25-30 g) were anaesthetised by an intra-peritoneal 
injection of 120 mg/kg body weight of sodium pentobarbitone. The liver was 
perfused with TKM buffer, as previously described, prior to dissection and 
homogenisation in homogenisation buffer. The homogenate was filtered through 4 
layers of cheesecloth and then centrifuged at 600 g for 10 minutes at 4°C. The pellet 
was washed in homogenisation buffer and then homogenised in centrifugation buffer
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on ice and centrifuged at 70,000 g  for 80 minutes at 4°C. Finally, the nuclei pellet 
was resuspended in buffer A at a final concentration of 2-3 x 10  ^nuclei/ml and stored 
at -70°C prior to use.
2.11.6 Reconstituted Cell-free system
Studies in the reconstituted cell-free system were undertaken as previously described 
(Chow et al., 1995; Kass et al., 1996). The reaction mixture containing 80 pg of 
thymocyte or 240 pg of hepatocyte supernatant protein and 5x10^ thymocyte nuclei 
or 3 X 10  ^ liver nuclei were diluted to a final volume of 30 pi with cell lysis buffer. 
The total activity of the cell extract present in the reaction was 0.116 pmol AFC 
liberated/min at 21°C at saturating substrate concentration ± 0.08 SEM (n=5) specific 
to Z-DEVD-AFC cleavage. Samples were incubated at 37°C for the time periods 
indicated before analysis. In some experiments partially purified bovine thymocyte 
PARP (200 ng) was used in place of nuclei and recombinant human caspase-3 at Ix 
or lOx total cell extract activity (0.2U or 2U where 2U represents 1.2 pmol of AFC 
liberated/min at 21°C at saturating substrate concentration) was used in place of cell 
extract.
2.12 Determination of protein concentration
Protein determination was performed as previously described by Lowry et al, (1951). 
The copper solution was prepared by mixing 1 ml of 1% (% ) CUSO4 , 1 ml of 2% (% ) 
potassium sodium tartrate and 100 ml of 2% (% ) Na2C0 3 . Folin reagent was also 
prepared by diluting Folin-Ciocalteu phenol reagent with milli-Q water (1:2). To 
tubes in duplicate, BSA fraction V and milli-Q water were added to give a standard
69
curve of 0-100 pg/ml. The reaction was started by adding 0.5 ml of 0.5 M NaOH and 
5 ml of the copper solution mixture to 0.5 ml aliquots of standards and previously 
diluted samples. The mixtures were mixed and left to stand for 10 minutes, followed 
by the addition of 0.5 ml Folin reagent. After 30 minutes, the absorbencies were read 
at 720 nm wavelength.
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Chapter 3
Kinetics of Fas-mediated apoptosis in 
isolated & cultured hepatocytes
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3.1 Introduction
Previous studies have been carried out in primary hepatocyte cultures (Ni et al., 1994; 
Rouquet et al., 1996a; Rouquet et al., 1996b) rather than freshly isolated hepatocytes. 
Although the same strain of mouse was used as hepatocyte donors as in the current 
experiments, the cells maintained in culture were nearly completely refractory to anti- 
Fas induced apoptosis unless inhibitors of protein synthesis (cycloheximide) or 
protein kinase C (H7) were present. Thus, a preliminary step was to establish a 
model using hepatocytes in cell suspension that is very different from those obtained 
with cultured cells, and provide an in vitro system that in kinetic and magnitude terms 
resembles more closely to the in vivo situation where apoptosis is induced in the 
whole liver within a few hours. (Ogasawara et al., 1993).
Cells respond to a variety of extracellular stimuli by activating different members of 
the MAPK signaling pathways. The MAPK pathways play a major role in a variety 
of different cellular processes and respond to mitogenic stimuli, cell stress, apoptotic 
stimuli etc. (for reviews see; Seger and Krebs, 1995; Robinson and Cobb, 1997; 
Lewis et al., 1998). These signaling pathways are important in regulating a number 
of different transcription factors often leading to transcriptional activation and 
synthesis of new proteins. MAPKs are also involved in phosphorylation of critical 
regulatory molecules or metabolically important proteins.
The MAPKs are proline-directed serine-threonine kinases recognising an optimum 
proline-X-threonine/serine-proline substrate sequence. A lesser degree of 
phosphorylation can be achieved when the first proline is missing (Clark et al., 1991). 
The activation of MAPKs requires dual phosphorylation on both a serine/threonine
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and a tyrosine site and if  either of the two sites is dephosphorylated the activity drops 
significantly. Interestingly, the MAPKs are the only kinases known to need this dual 
phosphorylation (Lewis et al., 1998). Activation of MAPKs usually results in their 
nuclear translocation. The MAPK family consists of at least three different signaling 
cascades: the ERKl/2, the JNK/SAPK and the p38 kinase pathways. These cascades 
all consist of three-kinase modules including a MAPK, which is activated by a 
MAPK kinase (MAPKK), which in turn is activated by a MAPKK kinase 
(MAPKKK). All MAPK pathways involve the same highly specific form of 
regulation, as the activating MAPKKs are dual specificity kinases, capable of 
phosphorylating threonine and tyrosine in the activation domain of ERKl/2, 
JNK/SAPK and p38 kinase.
The ERKl/2 pathway was the first MAPK pathway described. The pathway is 
usually stimulated by growth and differentiation factors, through upstream pathways 
that are mediated by enzyme-linked receptors such as the EGF receptor, G-protein 
coupled receptors such as the angiotensin receptor or by cytokine receptors such as 
the TNFRl. The main pathway leading to ERKl/2 activation consists of receptor 
tyrosine kinases activating Ras, a GTPase, which in turn binds to the MAPKKK Raf- 
1. This binding results in activation of Raf, which then activates the MAPKKs 
MKKl and/or MKK2 (Kyriakis et al., 1992; Robinson and Cobb, 1997; Lewis et al., 
1998). These dual specificity kinases then phosphorylate and activate the ERKl/2. 
To date, it is still not clear why these two isoforms of the ERKs and MKKs exist. 
Both ERKl/2 proteins are conserved in all eukaryotic species and they are expressed 
in high amounts in mammalian cells (Huang and Ferrell, 1996) with only a small 
variation between different tissues (Boulton et al., 1991a; Moriguchi et al., 1995).
73
ERKl/2 are serine/threonine kinases with molecular weights of 42 and 44 kDa, 
respectively, and a 90% sequence identity in mammalian cells (Boulton et al., 
1991b). Both have a conserved catalytic subunit, C-terminal extensions and a 25 
amino acid insert sequence between the subdomains 9 and 10. The ERKl/2 are 
activated by phosphorylation within their activation domain at Thrl 83-Glu-Tyrl 85, 
where phosphorylation of Tyr usually precedes phosphorylation of Thr (Haysted et 
al., 1992). The ERKl/2 can be distinguished from other MAPKs by the tri-peptide 
activation motif Thr-Glu-Tyr on which the dual phosphorylation occurs (Derijard et 
al., 1995). Phosphorylation of both residues is required to fully activate the ERKl/2 
whereas phosphorylation on one residue results in only a 10% activation (Robbins et 
al., 1993).
Quite curiously the PI-3K inhibitors Wortmannin and LY 294002 (Powis et al., 1994; 
Vlahos et al., 1994) inhibit ERKl/2 activation in response to several stimuli such as 
TCR, insulin, platelet-activating factor and growth hormone (Cross et al., 1994, 
Welsh et al., 1994; Ferby et al., 1994; Urich et al., 1995; Kilgour et al., 1996; von 
Willebrand et al., 1996; Sutor et al., 1999). This data is further supported by studies 
demonstrating suppression of ERKl/2 activation by expression of dominant-negative 
PI-3K and activation of ERKl/2 by constitutively active P1-3K (Hu et al., 1995; von 
Willebrand et al., 1996; Sutor et al., 1999).
Both transient and persistent activation of JNK/SAPK as well as its substrate c-jun 
has been associated with several apoptotic signals including cell stress, UV light 
irradiation, y-irradiation, and Fas and TNF R stimulation (Chen et al., 1996; Wilson
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et al., 1996; Bossy-Wetzel et al., 1997; Guo et al., 1998; Roulston et al., 1998). On 
the other hand, inhibition of the ERKl/2 signaling cascade has been observed in a 
number of cellular model systems undergoing apoptosis (Xia et al., 1995; Berra et al., 
1997; Jarvis et al., 1997). Furthermore, an increase of ERKl/2 activity has been 
shown to suppress apoptosis in different cellular model systems (Xia et al., 1995; 
Gardner and Johnson, 1996; Erhardt et al., 1999). In nerve growth factor-deprived 
PC-12 cells, the apoptotic response is due to increase in JNK/SAPK and p38 kinase 
activity and a decrease in ERKl/2 activity. Furthermore, dominant negative mutant 
proteins inhibiting either the JNK/SAPK or p38 kinase pathway or mutant proteins 
constitutively activating the ERKl/2 pathway negatively affected the apoptotic 
response (Xia et al., 1995). Similar results have been observed in apoptosis induced 
by ceramide or sphingomyelin (Jarvis et al., 1997) and oxidative stress (Wang et al., 
1998). These results indicate ERKl/2 signaling serves as a negative regulator of 
apoptosis, whereas p38 kinase and JNK/SAPK are likely to be positive regulators. 
Furthermore these results imply that the balance between JNK/SAPK, p38 kinase and 
ERKl/2 seems to be important for the fate of the cell. Although JNK/SAPK 
activation has been indicated in several studies as a pro-apoptotic signal, there is 
increasing evidence suggesting that both JNK/SAPK and the upstream activator 
MEKKl are capable of inducing (Widmann et al., 1998; Gibson et al., 1999a) as well 
as suppressing apoptosis (Nishina et al., 1997; Roulston et al., 1998; Assefa et al., 
1999; Yuiri et al., 1999). Since MEKKl has been shown to activate both the 
JNK/SAPK pathway as well as the ERKl/2 pathway (Yuiri et al., 1998) and the NF- 
kB  (Lee et al., 1997), it still remains to be elucidated which pathway(s) are 
responsible for the protective effect.
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Fas-mediated apoptosis is not only dependent on the expression levels of death 
effector molecules but also on the levels of the FasR and FasL as well as on the levels 
and activation status of signaling proteins with an inhibitory effect on the apoptotic 
machinery. The inhibitory signals consist of both protein synthesis-dependent and 
phosphorylation-induced signals that are not dependent on newly synthesised 
proteins. The most direct way to suppress a death receptor pathway is to inhibit FasL 
binding to a functional FasR. In this regard, a mechanism has been proposed 
whereby elevated expression of a soluble form of FasR would bind to the FasL and 
thereby rescue the target cells (Cheng et al., 1994). The FasR levels can also be 
upregulated or downregulated. In this sense, PKC activation has been shown to 
upregulate FasR levels in cells not expressing the FasR, thereby sensitising the cells 
for Fas-mediated apoptosis (Wang et al., 1997), whereas oncogenic Ras 
downregulates the FasR expression and suppresses Fas-mediated apoptosis (Fenton et 
al., 1998; Peli et al., 1999). A very interesting mechanism of neutralizing the ligand 
binding comes from the recently described TRAIL receptor studies, where binding of 
TRAIL to the decoy receptors binds the ligand without any effect on the cell (Pan et 
al., 1997; Sheridan et al., 1997). Interestingly, a similar neutralizing decoy receptor 
for the FasR has recently been described in colon and lung cancer cells (Pitti et al.,
1998). A further downstream level of regulating the sensitivity to apoptosis is to 
regulate the activity of the receptor. An ubiquitination-related pathway, involving 
sentrin, has been suggested to modulate the FasR activity. Sentrin, a protein with 
sequence similarities to ubiquitin, was found to bind to the death domains of CD95 
and TNFRl. When overexpressed, sentrin, suppresses apoptosis induced by these 
receptors (Okura et al., 1996). It is worth emphasising that expression of several 
proteins affecting Fas-mediated apoptosis are regulated by phosphorylation-based
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signaling. These proteins include the FasR (Fenton et al., 1998; Wang et al., 1997), 
the FasL (Anel et al., 1994; Brunner et al., 1996; Latinis et al., 1997), Bcl-2 (Itoh et 
al., 1993; Scaffidi et al., 1998), and c-FLIP (Irmler et al., 1997; Yeh et al., 1998).
The expression of inhibitory proteins always requires time for protein synthesis. The 
inhibitory proteins usually have a limited life span, dependent on their half-life, 
limiting the flexibility of the respective inhibitory pathways. In contrast, 
phosphorylation-based signaling occurs within seconds, affecting the target proteins 
immediately, thereby generating a very flexible and dynamic regulatory system. It is 
likely that the cells need to modulate their responsiveness to apoptotic signals quite 
quickly when a cell is in an environment with rapidly fluctuating conditions as during 
development or during an immune response. In situations like this, rapid modulation 
through phosphorylation-mediated signaling rather than through synthesis of protein 
inhibitors/activators could be beneficial. The ERKl/2 pathway is associated with T- 
cell activation, cell growth, and proliferation, and has consequently also been 
associated with suppression of apoptosis in several cell systems (Xia et al., 1995; 
Gardner and Johnson, 1996; Berra et al., 1997).
The PI-3K pathway has been indicated to have an inhibitory role in several forms of 
apoptosis. In accordance, PI-3K and the downstream target PKB/Akt have been 
implicated as inhibitory proteins in Fas-mediated apoptosis (Hausler et al., 1998; 
Rohn et al., 1998; Gibson et al., 1999b; Di Cristofano et al., 1999, van Parijs et al.,
1999). In this respect, suppression of PI-3K activity with the pharmacological PI-3K 
inhibitors LY294002 and Wortmannin, as well as by transient transfections using 
dominant negative forms of PI-3K and PKB/Akt enhances Fas-mediated apoptosis in
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different cell lines (Hausler et al., 1998; Rohn et al., 1998). Furthermore, in transient 
transfection studies, constitutively active PI-3K and PKB/Akt suppress Fas-mediated 
apoptosis (Hausler et al., 1998; Rohn et al., 1998). These studies also show that the 
PI-3K-mediated suppression affects apoptosis induced by overexpressing F ADD but 
not caspase-8, indicating that PI-3K exerts its effect downstream or at the level of 
caspase-8 activation. Also, the protective effect on Fas-mediated apoptosis, by the 
survival factors IL-2 and EGF, has been shown to be dependent of the PI-3K pathway 
(Gibson et al., 1999b and van Parijs et al., 1999). Although the JNK/SAPK pathway 
has been generally implicated as an apoptosis-promoting signaling pathway, MKK4 
and JNK/SAPK have, quite surprisingly, been indicated as possible inhibitory kinases 
in FasR-, TCR and TNFRl-mediated apoptosis (Nishina et al., 1997; Roulston et al., 
1998; Yuiri et al., 1998).
This chapter will initially validate the cell suspension system as a model to assess 
Fas-mediated apoptosis in freshly isolated murine hepatocytes alongside comparisons 
to primary hepatocyte cultures. Also, the role of protein synthesis and specific 
kinases by inhibition studies will be examined to elucidate the modulation of varying 
sensitivities to Fas-stimulation.
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3.2 Validation of cell suspension system
3.2.1 Kinetics of anti-Fas induced apoptosis in isolated hepatocytes
Subsequent to the successful development of a murine hepatocyte isolation method, 
the kinetics to the addition of Jo2, an activating monoclonal antibody directed against 
Fas (Yonehara, 1989), were investigated. Untreated cells maintained in suspension 
were viable as assessed by trypan blue for 7 hours without any detectable loss of 
viability (92% ±4% initially to 88% ±6% after 7 hours). The addition of Jo2 to 
freshly isolated mouse hepatocytes induced rapid apoptosis in approximately 80% of 
the hepatocyte population as assessed by plasma membrane blebbing and chromatin 
condensation (Fig. 7). A close dose-response relationship of the amount of anti-Fas 
antibody used in respect to apoptosis as assessed by plasma membrane blebbing and 
nuclear chromatin condensation can be seen (Fig. 8), with maximum induction 
occurring at 100 ng/ml. At this concentration of antibody, the earliest morphological 
signs of apoptosis were observed within 90 minutes of antibody addition. Analysis of 
the chromatin integrity in anti-Fas stimulated hepatocytes by agarose gel 
electrophoresis showed that Fas-mediated apoptosis was accompanied by the 
formation of DNA fragments in a time-dependent manner (Fig. 9). Noteworthy is the 
observation that in liver cells DNA fragmentation appeared to precede the 
morphological changes. Despite extensive apoptosis of the anti-Fas treated 
hepatocytes, the cells excluded trypan blue showing that the plasma membrane 
remained intact throughout the entire duration of the experiments (results not shown). 
Analysis by FIGE for high molecular weight DNA fragmentation yielded unclear 
results (results not shown). Consequently, only oligonucleosomal length DNA 
fragmentation was used to assess apoptosis.
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Figure 7: Morphological changes of apoptosis induced by anti-Fas antibody 
treatment in murine hepatocytes.
A control hepatocyte (A) and two typical apoptotic hepatocytes (B) following a three- 
hour incubation in the absence and presence o f anti-Fas antibody (100 ng/ml), 
respectively are shown. The cells were prepared as described under Materials and 
Methods and visualized using a Zeiss Axiovert fluorescence microscope connected to 
an MCID digitized video analysis system with a Dage-72 CCD camera. Two digitized 
frames o f the same cells corresponding to the light microscopic image and 
fluorescence staining o f the nuclei with Hoechst 33342 were acquired and merged to 
show combined whole cell and nuclear morphologies. Bar = 10 jUm.
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Figure 8: Dose-response curve of anti-Fas antibody induced apoptosis in 
hepatocytes.
Freshly isolated murine hepatocytes were incubated in the absence (D) or presence 
o f 10 ng/ml (MK), 50 ng/ml (O), 100 ng/ml (9) or 500 ng/ml (A) anti-Fas antibody. 
Apoptosis was assessed at the indicated time points by microscopy as described 
under Materials and Methods. The inset depicts the computed dose-response curve 
fo r  anti-Fas antibody induced apoptosis in hepatocytes.
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Figure 9: Time course of anti-Fas antibody induced formation of 
oligonucleosomal length DNA fragments in hepatocytes.
Freshly isolated murine hepatocytes were incubated in the absence or presence o f  
100 ng/ml anti-Fas antibody and at the indicated time points, aliquots o f  cell 
suspensions were taken and processed for agarose gel electrophoresis as described 
under Materials and Methods.
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3.2.2 Morphology of hepatocytes in cell culture
Fig. 10 shows the change in hepatocytes morphology from spherical shape in cell 
suspension to a smoother surface when plated onto poly-L-lysine. As illustrated in 
Figs. lOB and 11 A, cells in culture begin to spread after three hours forming a 
monoconfluent layer of cells.
3.3 Effect of protein synthesis and kinase inhibitors 
in cell culture and cell suspension
3.3.1 Effect of protein synthesis inhibition on Fas-mediated 
apoptosis
The effects of the protein synthesis inhibitors cycloheximide (50 pg/ml) and 
actinomycin D (50 ng/ml) on Fas-induced apoptosis were examined, and found that 
these agents did not alter Fas-mediated apoptosis of freshly isolated mouse 
hepatocytes maintained in suspension but, in agreement with other reports (Ni et al., 
1994; Rouquet et al., 1996a; Rouquet et al., 1996b), cycloheximide (CHX) restored 
the ability of cultured hepatocytes to respond to anti-Fas treatment (Fig. IIC). These 
findings indicate that inhibitors of protein synthesis are not required for hepatocyte 
apoptosis in the cell suspension system. The addition of CHX produced similar 
kinetics and level of induction of Fas-induced apoptosis in the cultured hepatocytes 
as those in cell suspension (Fig. 12A and B). The level of necrosis in cells incubated 
only with CHX was similar to that observed in controls, and low molecular weight 
DNA gel electrophoresis showed no detectable levels of necrosis. Thus, although 
CHX does not induce apoptosis, it can sensitise the cell, allowing CHX and anti-Fas 
antibody to be used as a model system in cell culture.
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Figure 10: Morphology of hepatocytes in cell culture and cell suspension as 
assessed by light microscopy
Freshly isolated murine hepatoctyes were cultured (0.6 xlO^ cells/well) or held in 
suspension (1.6x10^ cells/ml) and incubated with 200 ng/ml or 100 ng/ml anti-Fas 
antibody respectively/
(a) Hepatocytes from cell suspension showing an apoptotic body (a) and a general 
roundness in shape in normal cells (n).
(b) Hepatocytes from cell culture showing a flatter shape.
(c) Visualisation o f nuclei stained prepared from cell culture samples following a 3- 
hour incubation with anti-Fas antibody (200ng/ml) as described in Materials and 
Methods
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Figure 11: Morphological changes of cultured hepatocytes at 3 hours post­
treatment.
Cultured murine hepatocytes were incubated in the absence (A) or presence o f  
200ng/ml anti-Fas antibody (B) alongside cycloheximide (lOOpg/ml) (C), 
Wortmannin (50pM) (D) or PD089059 (ImM) (E) as described under Materials and 
Methods, (a) stands for apoptotic cell, (n) fo r normal cell and (s) for normal cultured 
cell undergoing spreading.
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Figure 12: Effect of cycloheximide over time in cell culture and suspension.
Freshly isolated murine hepatocytes were cultured at a density o f 0.2 x  10^ cells/ml 
on pre-coatedplates (A) or incubated in suspension at a density o f 1 .6x  10^ cells/ml 
(B) in the absence (D) or presence o f 200 ng/ml anti-Fas antibody (K) after pre­
treatment with 100 jlM  CHX (O) alone or in conjunction with anti-Fas antibody ( ^). 
Apoptosis was assessed by microscopy as described under Materials and Methods 
and each point is the mean ±SEM  o f at least three independent experiments.
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3.3.2 Effect of MAPKinase and PI3Kinase inhibition on Fas- 
mediated apoptosis
It was hypothesised the réfraction to anti-Fas antibody in culture was mediated by 
simulated MAPK pathway(s) possibly acting as inhibitors on the Fas death 
machinery. To investigate whether there was involvement of the MEK1/2-ERK1/2 
or PI3K mediated signaling pathways, their respective inhibitors, Wortmannin (Fig. 
1 ID) and PD089059 (Fig. 1 IE) were tested in cell culture.
The PD089059 (MEKl inhibitor) induced apoptosis when administered with the anti- 
Fas antibody in a similar profile as CHX with anti-Fas antibody (Fig. 13). However, 
unlike CHX, PD089059 (ImM) at three hours induced apoptosis as shown by low 
molecular weight DNA gel electrophoresis, thus demonstrating a need for MEKl 
activity for cell survival and a need for inhibition of MEKl to allow Fas-induced 
apoptosis to occur (Fig. 14A).
Interestingly, the administration of Wortmannin in the absence of anti-Fas antibody 
induced apoptosis within the first hour, which was further confirmed by DNA gel 
electrophoresis which showed the classical DNA fragmentation bands of apoptosis 
and not of necrosis (Fig. 14A). This would appear to imply that Wortmannin 
inhibited one or more primary survival pathways involving PI-3K.
3.3.3 Effect of Epidermal Growth Factor in Cell Suspension
Cell suspension can be rescued from apoptosis by the inclusion of EOF (Fig. 14B), 
but the effect diminishes over time (Fig. 15). EGF is known to bind the EGF receptor 
causing autophosphorylation of the specific regions of the intracellular receptor
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domain, facilitating the binding and activation of specific SH2 and SH3 domain 
containing proteins: PI-3K, PLCy, Srh, Grb2 which can activate a variety of signaling 
pathways, SAPK, PKC, ERK, ras and raf-1. This appears to be dose-dependent with 
500ng/ml giving inhibition after one hour.
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Figure 13: Effect of PD089059 at varying concentrations over time.
Freshly isolated murine hepatocytes were cultured at a density o f 0.3 x 10^ cells/ml 
on pre-coated plates and incubated in the absence (D) or presence o f200 ng/ml anti- 
Fas antibody (M) after pre-treatment with 100 jjM PD089059 (O) or ImM  
PD089059 ( or ImMPD089059 alone (A). Apoptosis was assessed by microscopy 
as described under Materials and Methods and each point is the mean ±  SEM o f at 
least three independent experiments.
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Figure 14: DNA fragmentation analysis of cultured and suspended hepatocytes 
with inhibitors
Wortmannin induced the formation o f DNA fragmentation in cultured hepatocytes 
(a), over a range with maximal induction occurring at lOmM. The addition o f  anti- 
Fas antibody (200ng/ml) to cultured hepatocytes induced apoptosis but at a lesser 
extent than when cycloheximide (lOOpg/ml) was present. Epidermal growth factor 
inhibited anti-Fas-induced DNA fragmentation and RGD induced DNA 
fragmentation independent o f Fas-stimulation in the cell suspension hepatocytes (b). 
Samples were taken after 180 minutes and subjected to agarose gel electrophoresis 
as described under Materials and Methods.
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Figure 15: Effect of Epidermal Growth Factor at varying concentrations over 
time.
Freshly isolated murine hepatocytes were incubated in the absence (D) or presence 
o f 100 ng/ml anti-Fas antibody (H) after pre-treatment with 100 ng/ml EGF (9), 
500ng/ml EGF (O) or 500ng/ml EGF alone (A). Apoptosis was assessed by 
microscopy as described under Materials and Methods and each point is the mean ±  
SEM o f at least three independent experiments.
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3.3.4 Effect of RGD on the rate of apoptosis in cell suspension
Other researchers have demonstrated that adhesion of cells to the appropriate 
substrata activates the integrin superfamily, which can rescue cells from anoikos 
(apoptosis due to lack of cell adhesion). The RGD sequence if contained within the 
frbronectin integrin is a requirement for binding of frbronectin proteins/matrix. 
Activation of such integrins has been shown to phosphorylate a tyrosine protein, 
FAKS, which in turn can activate other signaling molecules: PI3K, src and PLCy. 
The addition of a peptide containing the RGD sequence would mimic the effect of 
integrin activation induced by culturing in the isolated murine hepatocyte. Thus, it 
was speculated that the addition of RGD peptide in cell suspension would activate 
this integrin family and the subsequent survival pathway. However, this was not the 
case and DNA gel electrophoresis demonstrates the induction of apoptosis by anti- 
Fas antibody (Fig. 14B).
3.4 Discussion
Previous studies have been carried out in primary hepatocyte culture (Ni et al., 1994; 
Rouquet et al., 1996a; Rouquet et al., 1996b) rather than freshly isolated hepatocytes. 
Although the same strain of mouse was used as hepatocyte donors, the cells 
maintained in culture were nearly completely refractory to anti-Fas induced apoptosis 
unless inhibitors of protein synthesis (cycloheximide) or protein kinase C (H7) were 
present. Thus, our results reported here of hepatocytes in cell suspension are very 
different from those obtained with cultured cells, and provide us with an in vitro 
system that in kinetic and magnitude terms resembles more closely to the in vivo
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situation where apoptosis is induced in the whole liver within a few hours 
(Ogasawara et ah, 1993).
We examined the effects of the protein synthesis inhibitors cycloheximide (50 pg/ml) 
and actinomycin D (50 ng/ml) on Fas-induced apoptosis, and found that these agents 
did not alter Fas-mediated apoptosis of freshly isolated mouse hepatocytes 
maintained in suspension but, in agreement with other reports (Ni et al., 1994; 
Rouquet et ah, 1996a; Rouquet et ah, 1996b) cycloheximide restored the ability of 
cultured hepatocytes to respond to anti-Fas treatment. These findings indicate that 
inhibitors of protein synthesis are not required for hepatocyte apoptosis in our system.
Cycloheximide has been described as an eukaryotic protein synthesis inhibitor 
(Adams et ah, 1993). In the case of ELK-1 (Chen et ah, 1996; Gille et ah, 1995; Zinh 
et al, 1995), hyperphosphorylation by ERK and SAPK is required for conversion to 
the active state while hypophosphorylation returns it to the inactive state. The SAPK 
and ERK pathways appear to converge at the level of nuclear transcription factor Elk- 
1.
Down regulation of MAPK was seen within 60 minutes irrespective of the status of 
cellular protein synthesis. SAPKs inhibition normally occurs within 60 minutes but 
was fully blocked. These findings indicate that the components involving MAPK 
down-regulation are probably pre-existing and do not require de novo synthesis while 
SAPK inactivation requires new synthesis e.g. MKP-1, which is encoded in 
immediately early genes. Interestingly, other reports have implicated a similar
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activation pattern for ERK and SAPK upon Fas receptor activation (Holmstrom, 
2000).
In cultured hepatocytes, CHX could thus work via inhibiting the production of 
survival proteins e.g. the anti-apoptotic adapter belonging to the ced-4 family which 
appears to link bcl-2 to procaspases (Goillot et al., 1997; Chinnaiyan & Dixit, 1997; 
Wu et al., 1997; Park et al., 1996). Interestingly, a recently isolated phosphatase has 
been shown to bind the structurally predicted inhibitory domain on the Fas receptor
i.e. the 15 amino acids at the C-terminal (Yanagisawa et al., 1997; Wallach, 1997). 
Expression of this protein FLIP/FAP-1 has been demonstrated to be inhibited by 
cycloheximide and actinomysin D in DLD-1 cells that are resistant to FasL. This 
inhibition reverses the resistance to Fas-induced apoptosis. This information suggests 
that the CHX with anti-Fas antibody time dependent response could work through the 
long-term activation of SAPK kinase, and/or decrease in the levels of anti-apoptotic 
proteins.
In cell suspension, the exemption from requiring CHX to induce apoptosis is likely 
due to the cells being sensitive to apoptotic stimuli. However, as the level of 
apoptosis in the controls is less than 5%, the cell still requires the appropriate 
induction signal(s) to activate the constitutively expressed apoptotic machinery. 
These points suggest that in cell culture the addition of CHX may results in cellular 
activities similar to that observed in suspension producing a system primed for death 
upon appropriate stimuli.
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PD089059 is documented as an inhibitor of MEKl and was shown to induce 
apoptosis with anti-Fas antibody in culture hepatocytes in a similar profile to CHX 
and anti-Fas antibody. This implicates the inactivation of ERKl, which leads into the 
inhibition of protein synthesis. EIF4E is the protein responsible for recognition of the 
cell eukaryotic messages. This complex is necessary for efficient binding and correct 
positioning of the 40S ribosome subunit on the mRNA. Recently, it has been 
reported that the phosphorylation of eIF4E in response to insulin could be blocked by 
PD089059 (Ito et al., 1997). As ERKl itself does not phosphorylate eIF4E, other 
elements of the pathway are presumably needed. MnK-1 appears to be an attractive 
candidate as it is activated by ERK and phosphorylates Ser209 in vitro. ERKl is also 
involved in the phosphorylation of nuclear transcription factors. Thus it can not be 
ruled out that ERKl inhibition could also cause reduction in gene expression. There 
have been several reports suggesting a cellular basal ERK activity, which would 
correspond to constitutively expressed proteins. This study however cannot comment 
on the existence of such an activity, and it cannot elucidate if ERK2 is possibly 
activated at any time/condition. The mechanisms by which CHX activates these 
kinases are not known. However, the MEKl activity in itself does not result in the 
refractory nature of cultured hepatocytes, as PD089058 is unable to induce apoptosis 
within one hour. The PD089059 induction of apoptosis at the third hour indicates the 
possibility that protein synthesis is of importance. The reason CHX may not induce 
apoptosis itself as seen with PD089059 may be owing to its ability to prevent 
inactivation of SAPK.
Wortmannin has been used by researchers as a selective inhibitor of the p i 10 subunit 
of PI-3K. The PI-3K superfamily phosphorylates the hydroxyl group at position 3 on
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the inositol ring and inducing signals implicated in receptor-simulated signalling and 
in the regulation of membrane traffic. Several distinct classes of PI-3K have been 
determined based on their substrates (Vanhausebroeck et al., 1997). The principle 
family investigated to date is the PI-3Ks class 1, containing p85 (regulatory subunit) 
and p i 10 (catalytic subunit). These units dimerise in the cytosol and are activated at 
the membrane through a variety of stimuli; FAK, p38/HOG/MAPK Kinase 2, G a and 
By subunits, ras, growth factor receptors and has a number of effectors; PKB/AKT, 
PKC family, phospolipase D, p70 S6Kinase, rac. PKB/AKT (Lawrence and 
Abraham, 1997; Morte and Downward, 1997; Klippel et al., 1996) appears to be 
especially important as it regulates protein synthesis through S6K, glycogen synthase, 
E2F transcription factor. The result in this study points to Wortmannin inhibiting a 
number of systems through the inhibition of PI-3K.
Wortmannin inhibition has also been reported to increase caspase-3/CPP32-like 
activity correlating to the down regulation of bcl-2 (Mukasa et al., 1997). This could 
be through the phosphorylation of regulatory proteins for the activation of caspase- 
like proteases. BAD, a member of the bcl-2 family has been shown to be 
phosphorylated by raf-1 at serine residues, and that non-phosphorylated BAD 
heterodimerises with BcLi. PI-3K could induce the protein phosphorylation at serine 
residues through activation of PKC, which leads to the indirect regulation of the 
phosphorylation of bcl-2 family. Another possibility is that PI-3K products are 
required either directly or indirectly for the recruitment of bcl-2 to the membrane.
However, the interpretation of Wortmannin’s activity is complicated by the emerging 
ubiquitous nature in its ability to inhibit the protein kinase activity of mTOR, as well
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as PI-4K at similar concentrations as for PI-3K (Lawrence & Abraham, 1997). This 
study only allowed the conclusion that Wortmannin inhibits a fundamental 
protein(s)/process(es) required for cell survival in cell culture. This study does not 
indicate whether hepatocytes in cell suspension require this pathway for survival. An 
interesting observation is EGF’s ability to rescue hepatocytes in suspension from Fas- 
induced apoptosis. Stimulation of the EGF receptor induced a multitude of signalling 
molecules to be activated; PLCy, Grb2 and src. These mediators proceed to induce 
the activation of ERK, PKA and PI-3K. Reports have shown that cAMP, which 
activates PKA, saves hepatocytes from undergoing apoptosis in cell suspension. EGF 
may thus prevent Fas-induced apoptosis through the activation of cAMP, which 
highlights the role of energy stores and protein synthesis in cell survival.
While Fas-mediated apoptosis has been considered to be a result of caspase 
activation, the role of phosphorylation in initiation and regulation has only recently 
been emphasised. The ERKl/2 pathway is a possible phosphorylation-based 
signaling pathway that could be involved in suppression of Fas-mediated apoptosis as 
the activation of this pathway is often associated with stimulation of cell activation, 
differentiation and proliferation (for review see, Marshall, 1995; Lewis et al., 1998). 
The first indications in support of this hypothesis have been obtained from a study on 
PC-12 cells, showing that inhibition of ERKl/2 and activation of JNK/SAPK and p38 
kinase are critical for induction of NGF-deprivation-induced apoptosis (Xia et al., 
1995), from a study showing that fibroblast growth factor mediated protection against 
apoptosis requires ERKl/2 activation (Gardner and Johnson, 1996), and from a study 
indicating that suppression of ceramide-mediated apoptosis in Jurkat T-cells by
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sphingosine-1-phosphate is associated with activation of the ERKl/2 pathway 
(Cuvillier et al., 1996).
A recent report showing that ERKl/2 activation suppresses Fas-mediated apoptosis in 
Jurkat T-cells (Holmstrom, 2000) has been confirmed by three different groups (Yeh 
et al., 1998; Wilson et al., 1999; Ruiz-Ruiz et al., 1999). In this study the TPA- 
generated protective effect on Fas-mediated apoptosis in Jurkat T-cells was abolished 
by PD98059 treatment and transient transfection studies with constitutively active 
ERKl/2 suppresses Fas-mediated apoptosis in Jurkat T-cells (Wilson et al., 1999). 
The recent study by Ruiz-Ruiz and co-workers indicate two plausible mechanisms for 
PKC induced protection of Fas-mediated apoptosis in Jurkat T-cells. The first 
mechanism which is a result of moderate PKC activation would be ERKl/2- 
dependent and the second that functions when PKC is maximally activated would be 
independent of ERKl/2 activation (Ruiz-Ruiz et al., 1999). Finally, Yeh and co­
workers show that concavalin A induced ERKl/2 activation induces expression of 
FLIP which then suppresses Fas-mediated apoptosis in Jurkat T-cells (Yeh et al., 
1998).
The initial hypothesis that the integrin receptors produce an anti-apoptotic signal may 
not be the case based on the study, through the observation that the cells adhere to 
surfaces coated with poly-L-lysine in serum-free conditions. Poly-L-lysine utilises 
the principle that owing to the cell culture plates having a negative charge and lysine 
carrying a positive charge in physiological conditions, it can coat the plates giving an 
overall positive charge. The hepatocyte cell membrane is negatively charged and 
thus allows electrostatic interactions to occur between the cell and substrata. When
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these interactions are strong enough, the cell will adhere and start to flatten. Cultured 
hepatocytes will secrete frbronectin, collagen, lamin and other extracellular matrix 
proteins depending on the matrix medium. However, the formation of a satisfactory 
matrix requires at least 24 hours of culturing and for tight junctions to form between 
hepatocytes, 2-3 days. Importantly, both the D and L forms of polylysine (control 
conditions) have been used to demonstrate the requirement of frbronectin binding the 
integrin frbronectin receptor which activates the tyrosine kinase FAK, resulting in the 
subsequent activation of PI-3K and inhibition of apoptosis (Davis, 1996). However, 
in this system, the cells adhere through the electrostatic charges of the membrane and 
cell adhesion molecule (CAMs) rather than the integrin receptors. This would seem 
to imply that the cell shape plays a dominant role in apoptosis rather than adhesion 
itself (Ruoslahti, 1997; Chen et al., 1997). Analysis of capillary regression in vivo 
has revealed that dying capillary cells remain in contact with ECM fragments, thus 
suggesting that the cell foreshortening caused by ECM dissolution may be the signal 
that initiates the death program. Human and bovine capillary endothelial cells switch 
firom growth to apoptosis by using micropattemed substrates that contained ECM 
coated adhesive islands of decreasing size to progressively restrict cell extension. 
Cell shape was found to govern whether individual cells grow or die, regardless of 
the type of matrix protein or antibody used to mediate adhesion. Hence, it would 
seem to suggest that the nuclear shape plays a role in regulation which is supported 
by reports that ‘pulling’ on an integrin on the cell membrane can cause deformation 
and movement of the nucleus.
All these observations reflect a series of safety mechanisms to regulate inappropriate 
cells death, involving protein synthesis and regulation of signalling cascades. Further
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work would be needed to elucidate how these are mediated. Areas of interest would 
be protein synthesis, phosphorylation events and specific kinase activity and how 
these interact with the Fas-mediated apoptotic pathway.
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Chapter 4
Fas-mediated apoptosis in mouse 
hepatocytes involves the processing 
and activation of caspases
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4.1 Introduction
The apoptotic process can be induced by stimuli of the so-called “death receptors” 
such as the tumor necrosis factor (TNF) receptor 1, DR-3, DR-4 or Fas (APO-1, 
CD95) (Nagata, 1997). The Fas receptor is activated through oligomerization upon 
binding of its ligand (FasL) to its extracellular domain and the apoptotic signal is 
transduced through the so-called “death domain”. Recent 'work has revealed that the 
death domain of Fas interacts with the death domain found in other proteins, such as 
FADD/MORT-1 (Boldin et al., 1995; Chinnaiyan et al., 1995) and Daxx (Yang et al., 
1997) which in turn activate caspase-8 (MACH/FLICE/Mch5) and Jun N-terminal 
kinase, (Boldin et al., 1996; Muzio et al., 1996; Yang et al., 1997) respectively. 
Caspase-8 appears to be the apical member in a cascade comprising a rapidly 
growing family of proteases that are all genetically related to Caenorhabditis elegans 
CED-3, a gene that is essential for apoptotic cell death in the developing worm. 
Caspases were previously referred to as interleukin-Ip-converting enzyme (ICE)- 
related proteases (Yuan et al., 1993; Alnemri et al., 1996; Nicholson and Thomberry, 
1997) and they share similar features in that they require an aspartic acid at the 
cleavage site and are activated by cleavage at aspartic residues resembling their own 
targets (Alnemri, 1997; Nicholson and Thomberry, 1997). Although, when 
overexpressed in mammalian cells all cloned caspases induce apoptosis, in Fas- 
induced lymphocyte apoptosis only caspases -8, -1, -3 and possibly -7 appear to be 
involved in the death execution phase (Enari et al., 1995; Los et al., 1995; Chow et 
al., 1995; Slee et al., 1996; Enari et al., 1996; Armstrong et al., 1996; Boldin et al., 
1996; Muzio et al., 1996; Medema et al., 1997b).
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Work on Fas has generally focused on the cells of the immune system, yet the 
FasR/FasL system plays an important part in the pathogenesis of thyroiditis 
(Giordano et ah, 1997), diabetes (Chervonsky et ah, 1997) and fulminant hepatitis 
(Ogasawara et ah, 1993; Galle et ah, 1995; Kondo et ah, 1997). Little is still known 
about how apoptosis is controlled in many of the latter organs. Hepatocytes or 
hepatoma cells may be induced to apoptose by cholestatic bile acids (Kwo et ah,
1995) topoisomerase I inhibitors (Adjei et ah, 1996) transforming growth factor p 
(TGFp) (Oberhammer et ah, 1992) and TNFa (Shinagawa et ah, 1991). Hepatocytes 
also express high levels of the Fas receptor, which has been shown in vivo to result in 
the death of the animals through massive liver damage by intraperitoneal injection of 
anti-Fas antibody (Ogasawara et ah, 1993). The Fas/FasL system has since been 
implicated in the pathogenesis of viral and other forms of hepatitis (Nagata, 1997), 
yet at present the exact signalling cascade triggered by Fas in hepatocytes is unclear.
Previous studies carried out in primary hepatocyte cultures have shown that Fas- 
induced apoptosis may occur in vitro (Galle et ah, 1995; Ni et ah 1994; Rouquet et 
ah, 1996a; Rouquet, et ah 1996b; Nishimura et ah, 1997). However, cultured 
hepatocytes are very refractory to anti-Fas antibody treatment, as reported in the 
previous chapter, as compared to the in vivo situation where full destruction of the 
liver occurs within a few hours. In contrast, as reported previously, hepatocytes 
freshly isolated from mice remain highly responsive to Fas antigen stimulation and 
nearly the entire cell population becomes apoptotic within a few hours of stimulation 
by anti-Fas antibody. Using this validated experimental system, this chapter will 
examine the role of caspases and other proteases in the death response induced 
through Fas.
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4.2 Fas-mediated apoptosis of hepatocytes is sensitive 
to the action of protease inhibitors.
4.2.1 Effect of caspase inhibitors
Since proteases and particularly caspases appear to be the executioners of apoptotic 
cell death by Fas in lymphocytes (Enari et ah, 1995; Los et ah, 1995; Weis et ah, 
1995; Chow et ah, 1995; Slee et ah, 1996; Enari et ah, 1996; Armstrong et ah, 1996; 
Boldin et ah, 1996; Muzio et ah, 1996) their role in hepatocyte apoptosis was 
investigated. In the first approach, the involvement of caspases was examined using 
specific peptide inhibitors that are directed against the substrate cleavage site. On 
pre-treatment of hepatocytes with a range of different caspase inhibitors (for 45 
minutes) prior to addition of anti-Fas antibody, a dramatic reduction in apoptosis 
mediated by Fas antigen stimulation was observed (Table 4). The most striking 
protection from apoptosis was with Ac-DEVD-CHO and Z-VAD-FMK, which 
produced complete inhibition of apoptosis at 10 pM and 50 pM respectively, as 
assessed by both morphological changes (Fig. 16 and 17) and DNA fragmentation 
(Fig. ISA and results not shown). The other caspase inhibitors, Z-VAD-CMK, Ac- 
YVAD-CMK and Z-D-CK were less potent and only produced incomplete protection 
against Fas-mediated apoptosis (Table 4). None of the caspase inhibitors tested was 
toxic to hepatocytes as assessed by trypan blue uptake or morphological changes.
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Inhibitor Maximum dose 
tested
Percentage apoptosis 
Inhibited
Effect
DCI 25 pM 40%-60% Partial
TPCK 50 pM 40%-60% Partial
TLCK 100 pM <10% None
Calpain I inhibitor 100 pM <10% None
Calpain II inhibitor 100 pM <10% None
E-64 75 pM <10% None
Z-D-CK 75 pM 40%-60% Partial
Z-VAD-FMK 100 pM 80%-100% Complete
Z-VAD-CMK 100 pM 40%-60% Partial
Ac-DEVD-CHO 100 pM 80-100% Complete
Ac-YVAD-CMK 100 pM 40%-60% Partial
Table 4: Effect of different protease inhibitors on anti-Fas induced apoptosis in 
hepatocytes.
Freshly isolated murine hepatocytes at a density o f  1.6 x  10^ cells/ml were pre­
incubated with indicated concentrations ofprotease inhibitors for 45 minutes prior to 
the addition o f anti-Fas antibody (100 ng/ml). The data represents the result o f  
inhibition o f apoptosis obtained from at least three individual preparations.
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Figure 16: Effect of Ac-DEVD-CHO on anti-Fas induced apoptosis in 
hepatocytes
Freshly isolated murine hepatocytes were incubated in the absence (D) or presence 
o f 100 ng/ml anti-Fas antibody (M) after pre-treatment with 10 pM  Ac-DEVD-CHO 
(O) or 50 juM Ac-DEVD-CHO (A). Apoptosis was assessed by microscopy as 
described under Material and Methods and each point is the mean ±  SEM o f at least 
three independent experiments.
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Figure 17: Effect of Z-VAD-FMK on anti-Fas induced apoptosis in hepatocytes
Freshly isolated murine hepatocytes were incubated in the absence (D) or presence 
o f 100 ng/ml anti-Fas antibody (K) after pre-treatment with 10 juM Z-VAD-FMK (O), 
25 iM  Z-VAD-FMK (f),  50 pM  Z-VAD-FMK (A) or 100 pM  Z-VAD-FMK (A). 
Apoptosis was assessed by microscopy as described under Materials and Methods 
and each point is the mean dBEM o f at least three independent experiments.
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Figure 18: Inhibition of anti-Fas induced DNA fragmentation in hepatocytes by 
protease inhibitors.
The caspase inhibitor Z-VAD-FMK (A) and the serine protease inhibitor TPCK (B) 
inhibited the formation o f oligonucleosomal DNA fragments in freshly isolated 
murine hepatocytes treated with 100 ng/ml anti-Fas antibody. Samples were taken 
after 180 minutes and subjected to agarose gel electrophoresis as described under 
Materials and Methods.
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4.2.2 Effect of non-caspase protease inhibitors
Proteases that are unrelated to caspases have also been implicated in apoptosis in 
numerous cell types (Bruno et al., 1992; Kaufinann et al., 1993; Weaver et al., 1993; 
Voelkel-Johnson et al., 1995; Weis et al., 1995; Chow et al., 1995; Sarin et al., 1995; 
Feamhead et al., 1995; Vanags et al., 1996; Squier and Cohen, 1997) including 
hepatocytes (Zhivotovsky et al., 1994; Cain et al., 1995; Kwo et al., 1995; Roberts et 
al., 1997; Gressner et al., 1997) and hepatoma cells (Adjei et al., 1996). Here, the 
possibility that non-caspase proteases may also contribute to hepatocyte apoptosis 
following Fas antigen stimulation was investigated. By pre-treating hepatocytes with 
the serine protease inhibitors, DCI and TPCK for 45 minutes prior to the addition of 
anti-Fas, apoptosis was significantly attenuated but never completely blocked. 
Maximum effect on inhibition of apoptosis by DCI and TPCK occurred at 25 pM and 
15 pM, respectively, as assessed by morphological changes (Fig. 19 and 20) and 
DNA fragmentation (Fig. 18B and results not shown). In contrast, TLCK and the 
cysteine/serine protease inhibitor E-64 and the calpain inhibitors I and II did not 
protect from apoptosis (Table 4); on the contrary, both calpain inhibitors proved to be 
toxic to hepatocytes and were found to induce apoptosis by themselves (results not 
shown). Taken together, my results show that caspases and possibly additional serine 
protease(s) but not calpains contribute to liver cell apoptosis upon Fas activation.
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Figure 19: Effect of DCI on anti-Fas induced apoptosis in hepatocytes.
Freshly isolated murine hepatocytes were incubated in the absence (□) or presence of 
100 ng/ml anti-Fas antibody (■) after pre-treatment with 5 pM DCI (O), 10 pM DCI 
(• ) , 15 pM DCI (A) and 25 pM DCI (A). Apoptosis was assessed by microscopy as 
described under Materials and Methods and each point is the mean ± SEM of at least 
three independent experiments.
110
50 —
40 H
J2
"S
ü
o
’4—»
O
Q.
O
<
10  -
24090 120 150 2100 30 60 180
Time (min)
Figure 20: Effect of TPCK on anti-Fas induced apoptosis in hepatocytes.
Freshly isolated murine hepatocytes were incubated in the absence (□) or presence of 
100 ng/ml anti-Fas antibody (■) after pre-treatment with 5 pM TPCK (O), 15 pM 
TPCK (• ) , 50 pM TPCK (A). Apoptosis was assessed by microscopy as described 
under Materials and Methods and each point is the mean ± SEM of at least three 
independent experiments.
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4.3 Caspases are processed to their catalytically 
active forms during Fas-induced apoptosis.
4.3.1 Analysis of caspase activation
The results obtained with peptide inhibitors have provided evidence for the 
involvement of members of this family in the apoptotic process. Unfortunately, the 
low degree of specificity of the inhibitors towards individual members of the caspase 
family and the high concentrations required to overcome their poor membrane 
permeability (Margolin et al., 1997) restricts the ability to identify the individual 
members that participate in the death execution phase. In order to further identify the 
caspases involved in Fas-mediated hepatocyte apoptosis, their activation by 
microfluorometry. Western blot analysis and measurement of in situ proteolysis was 
examined. Using the fluorogenic substrates Z-YVAD-AFC and Z-DEVD-AFC, it 
was observed that the rate of Z-DEVD-AFC cleavage increased ten-fold upon anti- 
Fas antibody treatment, whereas the rate of Z-YVAD-AFC cleavage remained 
unchanged (Fig. 21A and B). Furthermore, the cleavage of Z-DEVD-AFC was 
highly sensitive to inhibition by Ac-DEVD-CHO. These findings show that caspase-1 
(ICE) and related enzymes are not activated in Fas antigen stimulated hepatocytes but 
that activation of members of the caspase-3 (CED-3/CPP32) subfamily may be 
critical to liver cell apoptosis. I also investigated whether the protection jfrom Fas- 
induced apoptosis by TPCK and DCI was due to the inhibition of caspase activation 
or whether these inhibitors acted on a pathway that is acting in parallel or 
downstream of the caspase pathway. Pre-incubation of hepatocytes with TPCK 
prevented the increase in the rate of Z-DEVD-AFC cleavage in anti-Fas stimulated 
hepatocytes (Fig. 21C) to a similar extent as it protected from apoptosis (Fig. 20). In 
contrast, the inhibition of Fas-mediated apoptosis by DCI occurred without inhibition
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of Z-DEVD-AFC cleavage (Fig. 21C), suggesting that DCI did not interfere with the 
ability of Fas to activate members of the caspase-3 subfamily.
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Figure 21: DEVD-AFC and YVAD-AFC cleavage in cell extracts from anti-Fas 
treated isolated murine hepatocytes.
Murine hepatocytes were isolated and incubated in the absence or presence o f  100 
ng/ml anti-Fas antibody for 5 hours. Cell extracts were then made and incubated 
with (A) 40 pMDEVD-AFC in the absence or presence o f  50 nMDEVD-CHO or (B) 
YVAD-AFC for 30 min. In (C), hepatocytes were pre-incubated with 25 fiM  DCI or 
75 pM  TPCK as described under Materials and Methods prior to addition o f  100 
ng/ml anti-Fas antibody for 5 hours. The cell extracts were assayed fo r  DEVD-AFC 
cleavage activity alongside a linearised AFC standard curve (0-5OpM). The 
liberation o f  AFC was continuously assessed by microfluorometry. Data shown are 
from the results o f  two separate experiments in duplicates and enzyme activity is 
expressed as pmol AFC liberated per mg protein per min.
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4.3.2 Analysis of caspase processing
Examination of the pro-forms of caspase-3 and caspase-7 by Western blot analysis 
revealed that indeed Fas-mediated hepatocyte apoptosis was paralleled by the 
processing of their pro-forms to their p29 forms by removal of their pro-domains 
(Fig. 22). In the case of caspase-7, further degradation took place, with the 
appearance of a fragment that corresponded to the size of the catalytically active 
forms (p i9; the smaller fragment is not recognized by the antibody). Unexpectedly, 
analysis of the pattern of caspase-3 degradation reveals that the p29 fragment 
(caspase-3 without pro-domain) was constitutively present in these cells. A decrease 
in the pro-form of caspase-3 was observed but the p i7 fragment was never observed 
in these studies.
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Figure 22: Processing of caspase-3 and-7 in Fas-induced hepatocyte apoptosis.
Murine hepatocytes were isolated and incubated in the absence or presence o f 100 
ng/ml anti-Fas antibody. At the indicated time points aliquots were removed from the 
cell incubation and subjected to SDS-PAGE followed by immunoblotting with an 
antibody directed against caspase-3 (A) or caspase-7 (B) as described under 
Materials and Methods. Positive controls are mouse Do-11-10 T cell hybridoma cells 
(A) and human Jurkat T lymphocytes (B) treated with phorbol 12-myristate 13- 
acetate (50 ng/ml) and thapsigargin (50 nM) for 20 h as described under Materials 
and Methods.
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4.4 PARP is not cleaved in apoptotic hepatocytes.
It has been shown extensively that PARP cleavage is an early marker for apoptosis 
for many different models and is a direct result of caspase activation (Lazebnik et al., 
1994). Therefore, I investigated the in situ proteolysis of PARP in anti-Fas-treated 
murine hepatocytes. It was found that in order to detect the 116 kDa PARP protein in 
hepatocytes a high concentration of protein was needed (45-90 pg protein/lane) as it 
is a low abundance protein in these cells, relative to murine thymocytes or Jurkat 
cells (20-30 pg). Unlike previous studies on other cell types, such as HL60 cells 
(Kaufinann et al., 1993) and U937 cells (Dubrez, et al., 1996), the 85 kDa cleaved 
fragment of PARP was not detected in hepatocytes even after 70% of the cell 
population was apoptotic following treatment with anti-Fas antibody (Fig. 23). No 
other immune reactive bands corresponding to lower MW fragments of PARP were 
detected (results not shown) and there was no decrease in the intensity of the 116 kDa 
band (Fig. 23), confirming that PARP remained intact and was not proteolytically 
processed in Fas-induced hepatocyte apoptosis. In contrast, the induction of 
apoptosis in Jurkat cells by Fas antigen stimulation (with a similar % of cells 
undergoing apoptosis that we found with hepatocytes) resulted in the near complete 
disappearance of the 116 kDa band with the appearance of a major band 
corresponding to -85 kDa.
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Figure 23: Analysis of PARP cleavage following-Fas-induced apoptosis in 
isolated murine hepatocytes.
Cells were incubated in the absence or presence o f 100 ng/ml anti-Fas antibody and 
at 5 hours were solubilised in loading buffer and subjected to SDS-PAGE followed by 
immunoblotting with anti-PARP monoclonal antibody C-2-10. The positive control 
lane (30 pg o f protein) was from Jurkat T lymphocytes that were induced to undergo 
apoptosis as described under Materials and Methods and showed PARP cleavage 
with the appearance o f the -85 kDa band (arrow head). The lanes contained 
hepatocytes (control and apoptotic) at two different protein concentrations [90 pg (a) 
and 45 pg (b)j.
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4.5 DISCUSSION
A great deal of knowledge on the signalling cascade involved in Fas-induced 
lymphocytes apoptosis has recently emerged and it is our current understanding that a 
self-amplifying cascade of caspases, of which caspase-8 is the apical protease, that 
are responsible for most if not all apoptotic changes (Nicholson and Thomberry, 
1997). This particular caspase is recruited and probably autoproteolytically activated 
through protein-protein interaction with FADD/MORT-1 among a complex of 
proteins that dock onto the cytoplasmic death domain of oligomerized Fas (Nagata, 
1997). Although the exact molecular ordering of the events following caspase-8 
activation remains to be fully established, caspase-3 appears to be a major death 
executioner in the Fas system in most cell types (Nicholson et al., 1995; Slee et al.,
1996). It is also clear now that other apoptotic stimuli, whether through death 
receptors such as TNFRl or through p53 or as induced by chemotherapeutic agents, 
all appear to operate through a similar caspase cascade (Nicholson and Thomberry,
1997), even though the apical caspase as well as the trigger mechanism in the latter 
cases remains to be clarified.
In the liver and hepatoma cells, considerable evidence has been presented showing 
that apoptosis when induced by agents such as cholestatic bile acids or topoisomerase 
I inhibitors involves serine proteases that are distinct from caspases but that may be 
related to the cathepsin family (Kwo et al., 1995; Adjei et al., 1996; Roberts et al., 
1997). Yet, caspases are clearly implicated in hepatocyte apoptosis induced by 
staurosporine (Cain et al., 1996), TGF-p (Inayat-Hussain et al., 1997), TNFa 
(Künstle et al., 1997) and, as shown here, by Fas. From the tripeptide and 
tetrapeptide inhibitor activity profile and the cleavage of fluorogenic peptide
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substrates, caspases related to the CED-3/caspase-3 subgroup are major contributors 
to the execution phase. The identity of the members of this caspase subgroup that are 
most critical in causing apoptosis is difficult due to their close relatedness. Caspase-3 
is often viewed as a key effector of the cellular destruction during apoptosis 
(Nicholson, et al., 1995) yet the catalytically active form of caspase-3 does not 
accumulate in apoptotic hepatocytes to any detectable extent whereas that of caspase- 
7 does. These findings suggest that caspase-7 may possibly play a greater role in 
inducing the apoptotic changes in Fas-stimulated hepatocytes. Assuming that the 
murine Fas receptor also recruits FADD/MORT-1 and caspase-8, my findings would 
be consistent with a model where Ac-DEVD-CHO acts primarily at the level of 
caspases related to caspase-3, and -1 (Margolin et al., 1997), whereas Z-VAD-FMK 
appears to act on an upstream target (MacFarlane et al., 1997) possibly caspase-8 
(Medema et al., 1997b). Indeed, caspase-8 is highly sensitive to Z-VAD-FMK 
(Medema, et al., 1997b; Sek C. Chow, unpublished observations) and this would 
corroborate its general potency as an inhibitor of Fas-mediated apoptosis considering 
the early involvement of caspase-8 in the Fas signalling pathway (Boldin et al., 1995; 
Chow et al., 1995; Medema et al., 1997b; Muzio et al., 1996; Slee, et al., 1996). Two 
other laboratories very recently reported a similar pattern of inhibition (Rouquet et 
al., 1996a; Rouquet et al., 1996b; Künstle et al., 1997). Likewise, the systemic use of 
caspase inhibitors or overexpression of Bcl-2 which is believed to prevent the 
activation of caspases (Hengartner, 1997) has also been found to protect animals from 
fulminant hepatitis and lethality induced through anti-Fas injection (Lacronique et al., 
1996; Rodriguez et al., 1996; Rouquet et al., 1996b; Künstle et al., 1997) again 
corroborating the important role of caspases in Fas-mediated liver cell apoptosis.
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The closeness of the Kj values for the different caspases (Margolin et al., 1997) and 
the fact that the use of all currently available caspase inhibitors typically necessitates 
pM concentrations for inhibition to be seen in intact cell systems versus nM to 
completely block the recombinant proteases makes any assignment to individual 
caspases very challenging. When assaying hepatocyte extracts for caspase activities 
using the fluorogenic peptides Z-YVAD-AFC and Z-DEVD-AFC, only the latter 
activity was found to be increased thereby ruling out a contribution of caspase-1 in 
the apoptotic pathway triggered by Fas in mouse hepatocytes. Thus, also in cells that 
are not part of the immune system (Slee et al., 1996; Sarin et al., 1996; Martins et al., 
1997a; Smith et al., 1997), caspase-1 does not appear to be involved in the Fas 
mediated apoptotic process. Likewise, caspase-1 null mice develop normally and that 
there are no apparent defects in the apoptotic process (Li et al., 1995).
An unexpected finding of this work was that despite strong evidence for the 
activation of caspase(s) able to process Z-DEVD-AFC in an Ac-DEVD-CHO- 
sensitive manner, there was no cleavage of the DEVD motif-containing protein 
PARP. Most human caspases related to caspase-3 will process PARP to the 85 kDa 
form through cleavage at the DEVD recognition site (Nicholson et al., 1995; 
Lazebnik et al., 1994; Alnemri, 1997; Nicholson and Thomberry, 1997) and in cells 
undergoing apoptosis, caspase-3 is one of the major caspases responsible for its 
cleavage (Tewari et al., 1995). However, my data shows that the liver enzyme is not 
cleaved under apoptotic conditions. Similar results have very recently been reported 
by Inayat-Hussain et al, (1997) who showed that the induction of apoptosis in rat 
hepatocytes by TGF-P also occurs in the absence of PARP processing. Likewise, 
human Hep3B hepatoma cell apoptosis upon treatment with a topoisomerase-1
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inhibitor proceeds without detectable proteolysis of PARP (Adjei et al., 1996). PARP 
was found in hepatocytes at much lower levels than in lymphocytes and as a result I 
had to use much more cellular protein than routinely used with lymphocytes which 
had to be loaded onto the gels before PARP could be visualized. Thus, it appears that 
the lack of PARP proteolysis is a general feature of liver cell apoptosis, and my 
findings further corroborate the contention that PARP cleavage does not contribute to 
the death execution phase in apoptosis (Wang et al., 1995; Leist et al., 1997b).
The simplest rationale for the lack of PARP cleavage would be that its low 
abundance in hepatocytes might preclude efficient cleavage by caspases. 
Alternatively, PARP may be a poor substrate for the mouse caspases. Given the high 
degree of phylogénie conservation among the members of the caspase family this 
explanation would appear unlikely. Yet, Van de Craen et al., (1997) recently 
reported that with the murine homologues to human caspase-1, -3, -4, -6, and -7, only 
caspase-3 was found to process PARP, although all induced apoptosis when 
transiently overexpressed in a variety of mammalian cells. In Fas antigen-stimulated 
hepatocytes, pro-caspase-7 was fully processed to the catalytically active fragments, 
p i 9 (and presumably p i2). In the case of caspase-3, which was nearly entirely found 
to exist as p29 (i.e. lacking the pro-domain), the p i7 subunit was not detected in this 
work. Inefficient cleavage of p29 or rapid removal of p l7  once formed may be the 
reason for this apparent lack of detectable p l7  formation. Rodriguez et al., (1996) 
also only detected a very faint band corresponding to p i7 fragment of caspase-3 by 
Western Blot analysis of whole liver extracts following in vivo injection of the anti- 
Fas antibody Jo2, confirming that the catalytically active form of caspase-3 does not 
accumulate to the same extent as found in other cell types. Consequently, the
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inefficient activation of caspase-3 may also contribute to the lack of PARP cleavage 
in mouse hepatocytes.
The serine protease inhibitors DCI and TPCK, but not TLCK, partially inhibited anti- 
Fas induced morphological changes as well as DNA firagmentation. Both DCI and 
TPCK have been previously shown to prevent anti-Fas induced apoptosis in Jurkat 
cells (Weis et al., 1995, Chow et al., 1995) as well as in other apoptotic systems 
(Weaver, et al., 1993). The selectivity of TPCK and DCI for serine proteases is not 
absolute, and, therefore the possibility that also these agents may affect cysteine 
proteases cannot be neglected. However, these inhibitors do not appear to directly 
inhibit caspases (Lazebnik et al., 1994; Song et al., 1996; Xue et al., 1996). 
Consequently, additional proteases that are not related to caspases but that may be 
serine proteases, appear to contribute to Fas-mediated hepatocyte apoptosis. DCI did 
not prevent the increase in Z-DEVD-AFC cleavage activity whereas TPCK blocked 
Z-DEVD-AFC cleavage activity to a similar extent as it affected Fas-induced 
apoptosis. These findings suggest the contribution of possibly more than one serine 
protease in the apoptotic response. It should be noted that DCI and TPCK never 
completely blocked Fas-mediated hepatocyte apoptosis but only delayed its progress, 
whereas the onset of apoptosis was completely blocked by peptide inhibitors of 
caspases. Consequently, whereas caspases are the main executioners of the 
hepatocyte apoptosis in response to Fas, the role of the serine proteases targeted by 
TPCK and DCI appears to be to accelerate the completion of the apoptotic response 
by the caspase cascade.
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The identity of the proteases inhibited by TPCK and DCI as well as their exact 
position within the apoptotic protease cascade need to be clarified. On the basis of 
my inhibitor studies this protease activity seems to be distinct from the TLCK- 
sensitive protease described by the laboratory of Gores (Kwo et al., 1995) that has 
been shown to play an important role in bile acid-induced hepatocyte apoptosis and 
recently identified as a member of the cathepsin family of proteases (Roberts et al.,
1997).
Hence, this study shows that the mechanism of Fas-induced hepatocyte apoptosis 
involves caspases, in particular caspase-7 and possibly caspase-3, as well as a 
TPCK/DCI-sensitive serine-type protease(s). However, unlike in other cell types, 
Fas-induced apoptosis of hepatocytes is not characterized by proteolytic cleavage of 
PARP, and so further studies are required to elucidate why this is the case which 
form the next part of this project. It is possible that this part of the death machinery is 
redundant in hepatocytes. Future work should also address the nature of the 
TPCK/DCI-sensitive protease(s) and establish their position within the caspase 
cascade activated by Fas.
Further recent reports investigating the role of caspases in Fas-mediated apoptosis 
have shown their importance in the signaling pathway. A study showed in vivo 
evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes, by 
injecting caspase-3 deficient mice with anti-Fas antibody (Woo et al., 1999). Wild- 
type mice died rapidly owing to massive liver damage, whereas the survival of 
caspase-3 deficient mice was increased owing to a delay in hepatocyte cell death. 
What was of interest was the lack of mitochondrial cytochrome c release in the
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presence of intact bcl-2. An earlier study examined the role of caspase-1 and -3 in 
Fas-mediated apoptosis in vitro (Zheng et al., 1998). Hepatocytes isolated from 
caspase-1 and caspase-3 deficient mice along with wild-type controls were 
apoptotically induced by FasL. The rate of cell death were similar in all conditions, 
though caspase-3 deficient hepatocytes displayed significantly different 
morphological changes as well as significantly delayed DNA fragmentation. This 
was also observed in caspase-3 deficient thymocytes.
The specific roles of the various caspases have been shown to be dependent on 
varying factors including the cell type and apoptotic stimuli. In one study, caspase-1 
which was previously thought to be the central mammalian caspase, was shown not 
to be involved in Fas-mediated apoptosis in Jurkat cells, as determined through 
peptide based inhibitors (Chow et al., 1999). Furthermore, no pro-caspase-1 protein 
or the activated form of the protein was detected and even the introduction of 
recombinant caspase-1 with control cell lysates did not activate the apoptotic 
pathway.
It has been widely accepted that apoptotic cell death generally involves the activation 
of caspases. However, the exact role of the mitochondria has yet to be determined. 
On induction of an apoptotic signal, the signal transduction pathway converges upon 
the mitochondria and initiates the release of cytochrome c to the cytoplasm. It has 
been shown recently that caspases mediate cytochrome c release from mitochondria 
in Jurkat cells induced to undergo apoptosis by Fas stimulation (Bossy-Wetzel and 
Green, 1999). The caspase inhibitor Z-VAD-FMK inhibited this event. In another 
report it was shown that caspase-8 cleaves BID, a BH3 domain-containing pro-
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apoptotic bcl-2 family member in the Fas mediated signalling pathway (Li et al,
1998). Full length BID (p22) is located in the cytosol, where on cleavage it migrates 
to the mitochondria, thus transducing the apoptotic signal from the cytoplasmic 
membrane to the mitochondria. Cleaved BID (p i5) initiates the clustering of 
mitochondria around the nuclei and release of cytochrome c independent of caspase 
activity, and then loss of mitochondrial membrane potential, cell shrinkage, and 
nuclear condensation in a caspase-dependent fashion. Subsequent research in vivo 
showed that in anti-Fas antibody induced apoptosis, p i5 BID in the cytosol of 
hepatocytes translocates to the mitochondria, releasing cytochrome c (Gross et al.,
1999). However, in the presence of bcl-xi/blc-2 the release of cytochrome c was 
prevented though other morphological changes transpired along with cell death.
The importance of the interaction between caspases and the mitochondria via BID 
was further demonstrated by studies using BID deficient mice (Yin et al., 1999). On 
injection with anti-Fas antibody, mice deficient for BID nearly all survived whereas 
wild-type mice died from hepatocellular apoptosis and haemorrhagic necrosis. About 
half of the BID-deficient mice had no apparent liver damage and showed no evidence 
of the activation of caspases -3 and -7, though caspase-8 had been activated. The 
other BID-deficient mice survived with modest damage with caspases -3 , -7, -8 being 
activated but their nuclei were intact and no mitochondrial cytochrome c was 
released. This was also seen in isolated thymocytes and hepatocytes from BID 
deficient mice, though another study showed that whereas BID-deficient hepatocytes 
were resistant to Fas-mediated apoptosis, thymocyte and embryonal fibroblasts were 
not (Nagata, 1999). These reports would suggest that BID is a critical substrate in 
vivo which mediates a mitochondrial amplification loop, linking the caspase cascade
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to mitochondrial release of cytochrome c. The link between mitochondria and 
caspases has been further demonstrated by a recent report which showed the 
mitochondrial release of caspases -2 and -9  during apoptosis (Susin et al., 1999). 
The study suggested that caspase-2 and -9  zymogens are localised in mitochondria 
and that disruption of the outer mitochondrial membrane during apoptosis may be a 
critical factor in their subcellular redistribution and activation.
The role of Fas in the liver has been investigated further in recent reports. One study 
examined whether regenerating hepatocytes die by the same apoptotic process as 
quiescent hepatocytes (Takehara et al., 1998/ This was investigated by injecting 
anti-Fas antibody into sham-operated mice or two-thirds partially hepatectomized 
mice. The onset of hepatocyte cell death was delayed in hepatectomized mice 
compared to controls. It was shown that the activation of caspase-3 was suppressed 
in those mice, where-as pro-caspase-3 expression was not altered. Furthermore, pre­
injection of untreated mice with TNFa suppressed caspase-3 activity and prolonged 
animal survival after Fas stimulation. These results suggest those Fas-signaling 
events at the level or upstream of caspase-3 are suppressed during liver regeneration, 
resulting in delayed hepatocytes apoptosis and that TNFa acts as a protective factor.
In summary, it would seem that caspases and other protease play an important role in 
Fas-mediated apoptosis in hepatocytes. Emerging evidence is showing the role of 
mitochondria as a central regulator between the caspase cascade and late stage 
apoptotic effectors. The exact signalling pathway of Fas-mediated apoptosis in the 
liver is being further understood and what role this plays in the organism.
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Chapter 5
Liver Poly (ADP-ribose) 
polymerase is resistant to cleavage
by caspases
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5.1 Introduction
Apoptosis is induced by a wide variety of agents and conditions including toxins, 
chemotherapeutic agents, radiation, viruses, heat and cold shocks and physiological 
activators such as tumour necrosis factor or Fas ligand. Recently a family of cysteine 
proteases, the caspases, has been shown to play a pivotal role as intracellular 
executioners of apoptosis (Cohen, 1997). This family of proteases share sequence 
homology to the Caenorhabditis elegan ’s CED-3, a gene essential for programmed 
cell death in the developing worm. The caspases have an absolute specificity for 
aspartate residue at the PI position and are themselves activated by cleavage at 
aspartate residues. During apoptosis, it is thought that the family of caspases forms a 
cascading proteolytic system.
Numerous endogenous substrates for caspases have been identified for varying 
caspases, and these include nuclear lamins (Takahashi et al., 1996), the inhibitor of 
caspase-activated DNase (ICAD) (Enari et al., 1998), sterol regulatory element- 
binding protein (Wang, et al., 1995), and the 70 kDa protein component of the U1 
small nuclear ribonucleoprotein (Tewari et al., 1995). Perhaps the best studied 
substrate is the DNA repair enzyme, poly(ADP-ribose) polymerase (PARP) 
(Kaufinann, et al., 1993; Lazebnik, et al., 1994). This enzyme is a zinc binding 
protein and binds to DNA via two zinc fingers with very high affinity (de Murcia and 
de Murcia, 1994). PARP uses NAD"  ^ as a substrate, linking poly(ADP-ribose) 
moieties to cleavable sites in DNA, thus allowing structural integrity to be maintained 
until base excision repair can be undertaken by DNA polymerases (Althaus and 
Richter, 1987). The enzyme exists as a 116 kDa protein, which on proteolytic 
cleavage by caspases is degraded to firagments corresponding to the approximate
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molecular weight mass of 24 kDa and 85 kDa. The two fragments represent the N- 
terminal DNA binding domain and the C-terminal catalytic domain of PARP. Most 
if not all inducers of apoptosis have been shown to lead to PARP cleavage during 
apoptosis. Consequently, the cleavage of PARP is widely accepted as a marker of 
apoptosis. It is now established that caspase-3 is responsible for the proteolytic 
cleavage of PARP (Tewari, et al., 1995; Nicholson et al., 1995) during apoptosis, 
although PARP cleavage has also been obtained using caspases -4,-5,-7 and -8 in 
vitro (Nicholson and Thomberry, 1997).
In the previous chapter, it was shown that Fas-mediated apoptosis of mouse 
hepatocytes involved the processing and activation of caspases, in particular caspase- 
7 and caspase-3 (Jones et al., 1998). However, no PARP cleavage was evident (Jones 
et al., 1998) even though high levels of caspase-3-like activity, cleaving the 
fluorogenic substrate, benzyloxycarbonyl-Asp-Glu-Val-Asp-7-amino-4-trifluoro- 
methylcoumarin (Z-DEVD-AFC) was identified in apoptotic hepatocytes. This 
substrate corresponds to the actual recognition and cleavage site present in PARP (- 
DEVDnI'G) for caspase-3 and related isoforms (Lazebnik et al., 1994). This is in clear 
contrast to other cell types of mouse or human origin where PARP proteolysis occurs 
during apoptosis (Kaufinann et al., 1993). Furthermore, Fas-induced apoptosis was 
completely abrogated by DEVD-CHO, a competitive inhibitor of caspase-3 and 
related caspases that is based on the tetrapeptide cleavage motif identified in PARP 
(Nicholson et al., 1995). These findings raise the possibility that either liver PARP is 
refractory to cleavage by caspase-3 and related caspases or that the caspases cannot 
access nuclear PARP during the apoptotic process. In this chapter, the reasoning why
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PARP is not cleaved in mouse liver cell apoptosis was investigated using a cell free 
system (Chow et al., 1995).
5.2 Validation of cell-free assay system
The previous chapter showed that mouse liver PARP was not cleaved during anti-Fas 
induced apoptosis in isolated hepatocytes (Jones et al., 1998). To examine why 
PARP was not cleaved, a cell-free system was set up consisting of isolated liver 
nuclei and apoptotic cell extracts from Fas-stimulated mouse hepatocytes and 
dexamethasone-treated thymocytes, respectively. The cell extracts derived from 
apoptotic thymocytes had on average a three-fold higher specific activity (1,450 pmol 
AFC liberated/min/mg) when compared with apoptotic hepatocyte cell extract (450 
pmol AFC liberated/min/mg) in terms of Z-DEVD-AFC cleavage. For comparative 
purposes, extracts from apoptotic thymocytes or hepatocytes were normalised for Z- 
DEVD-AFC cleavage activity prior to use in all subsequent experiments. As shown 
in Fig. 24A-C, both extracts from apoptotic thymocytes and hepatocytes, using 
identical Z-DEVD-AFC cleaving activities, were able to induce apoptotic nuclear 
morphology and DNA fragmentation in nuclei isolated from hepatocytes or 
thymocytes. There was no detectable difference in time course (kinetics) between the 
extracts from hepatocytes or thymocytes in their abilities to induce those apoptotic 
changes. Control cell extracts from both untreated cells had no affect on either 
hepatocyte or thymocyte nuclei (data not shown).
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Figure 24: Morphological changes of apoptosis and DNA fragmentation in 
isolated nuclei induced by cell extracts.
Cell extracts from mouse thymocytes (T) and hepatocytes (H) following 4 hours 
treatment with IpM  dexamethasone or 100 ng/ml anti-Fas antibody were prepared 
as described in Materials and Methods. Isolated mouse liver nuclei or rat thymocyte 
nuclei were incubated for 180 minutes with cell extracts (total DEVD-AFC activity o f  
0.116 pmol AFC liberated/min) and processed for agarose gel electrophoresis as 
described in Materials and Methods (A), or visualised using a Zeiss Axiovert 
fluorescent microscope connected to an MCID digitised video analysis system with a 
Dage-72 CCD camera (B and C). Digitised frames showing fluorescent staining o f  
liver (B) and thymocyte (C) nuclei with Hoechst 33342 were acquired. Bar—5pm.
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5.3 Analysis of PARP Cleavage
Despite the apoptotic morphology and DNA fragmentation induced by the apoptotic 
hepatocyte cell extracts in isolated liver nuclei, there was no reduction in the intensity 
of the 116 kDa PARP protein band or the appearance of the 85 kDa cleavage product 
(Fig. 25A) or any other immune reactive bands corresponding to lower molecular 
weight fragments of PARP (data not shown). Similarly, apoptotic hepatocyte cell 
extracts failed to induce PARP cleavage in isolated thymocyte nuclei. However, 
when partially purified PARP from bovine thymus was incubated with apoptotic 
hepatocyte extract, the 85 kDa signature cleavage product of PARP (Fig. 25B) was 
observed. Taken together, these results show that the PARP cleaving caspases in the 
hepatocyte extract do not cleave PARP in isolated nuclei but will readily cleave 
partially purified PARP to the 85 kDa fragment. This is in clear contrast to the 
apoptotic thymocyte extracts, which induced rapid and complete cleavage of PARP 
in thymocyte nuclei. In fact, thymocyte extracts were extremely efficient in cleaving 
PARP as indicated by the disappearance of the 116 kDa band after 90 minutes with 
only a transient appearance of the 85 kDa fragment at 5 min (Fig. 25C and data not 
shown). This shows that once formed, the 85 kDa fragment was further degraded by 
the proteases present in thymocyte extracts. However, thymocyte extract was unable 
to cleave PARP when incubated with isolated hepatocyte nuclei. PARP cleavage in 
thymocyte nuclei was completely inhibited by 25 nM Ac-DEVD-CMK (Fig. 25D) 
corroborating the specificity of the cleavage reaction by caspases.
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Figure 25: Analysis of PARP cleavage in isolated thymocyte and liver nuclei 
treated with cell extracts.
Cell extracts were prepared from isolated mouse hepatocytes (H) untreated or 
treated with 100 ng/ml anti-Fas antibody and from mouse thymocytes (T) untreated 
or treated with 1 juM dexamethasone. Isolated rat thymocyte nuclei and mouse liver 
nuclei were incubated with either apoptotic hepatocyte cell extract (A) or apoptotic 
thymocyte cell extract (C) and samples analysed fo r  PARP cleavage at indicated time 
points as described in Materials and Methods. Purified PARP was incubated with the 
apoptotic cell extracts fo r  180 minutes (B) prior to analysis. The positive control 
lane (20 pg) o f  protein was from Do-11-10 mouse T cell hybridoma cells treated with 
50 nM  thapsigargin and 50 nM  TP A fo r  20 hours as described in Materials and 
Methods. In D, apoptotic thymocyte cell extracts were pre-incubated fo r  20 minutes 
with 0-100 nM  Ac-DEVD-CMK prior to incubation with thymocyte nuclei.
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5.4 Assessment of PARP accessibility to caspases.
A possible reason for the lack of PARP cleavage in mouse liver nuclei could be due 
to the inaccessibility of caspase-3 or caspase-3 related caspases to the PARP protein. 
However, on incubation of apoptotic hepatocyte and thymocyte extracts for 180 
minutes with isolated liver nuclei that had been sonicated for 20 seconds to disrupt 
the nuclear envelope and fragment the chromatin, there was no processing of the 116 
kDa PARP protein or reduction in the intensity of the band (Fig. 26A). To further 
test this hypothesis, recombinant caspase-3 at Ix and lOx total cell extract activity 
was used in place of cell extract. Purified PARP was proteolytically cleaved as 
shown by a reduction in the 116 kDa band and an increasing appearance of the 85 
kDa cleaved fragment (Fig. 26A). However, PARP in intact or sonicated liver nuclei 
was resistant to cleavage by recombinant caspase-3 even when added at 10 times the 
DEVD-AFC cleavage activities found in the cell extract (1.2 pmol AFC 
liberated/min). A notable observation was that in intact thymocyte nuclei, 
recombinant caspase-3 induced clear and complete proteolysis of PARP without 
inducing any apoptotic morphological changes or DNA fragmentation (Fig. 26B and 
data not shown). This suggests that caspase-3 can get into the nuclei and cleave 
PARP.
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Figure 26: Lack of PARP processing in liver nuclei by recombinant caspase-3.
Isolated mouse liver nuclei and thymocyte nuclei were kept intact or sonicated prior 
to incubation with recombinant human caspase-3 as described in Materials and 
Methods. Purified PARP, intact and sonicated mouse liver (A) and thymocyte nuclei 
(B) were incubated with recombinant caspase-3 or apoptotic hepatocyte (Hep) or 
thymocyte (Thy) cell extract for 30 minutes. Recombinant easpase-3 was added to 
give either the same DEVD-AFC cleavage activity as in the cell extract (Ix which is 
equal to 0.12 fjmol AFC liberated/min) or ten times the activity (lOx which is equal to 
1.2 jumol AFC liberated/min).
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5.5 Caspase-3 activation in cell extracts
Alternatively, active caspase-3 may not be formed in sufficient quantities to 
efficiently cleave PARP or once formed there may be rapid removal of the active 
subunits. Even despite high DEVD-AFC cleavage activity, there may not be 
sufficient caspase-3 in hepatocyte extracts to process PARP. Although most caspases 
have been found to cleave PARP in vitro, a recent report by Van de Craen found that 
among cloned mouse caspases, only caspase-3 was capable of processing PARP 
when expressed in XY2 cells (Van de Craen et al., 1997). Indeed in agreement with 
my previous findings, the active p i7 fragment of caspase-3 was not observed in the 
hepatocyte extract despite clear evidence of zymogen processing, whereas it was 
clearly present in extracts from dexamethasone treated thymocytes (Fig. 27). The 
lack of detectable p i7 fragment raises the possibilities that either there is inefficient 
processing of p29 or rapid removal of p l7  once formed. Caspase-3 was also detected 
in hepatocyte and thymocyte nuclei as its pro-form with the p29 fragment also 
present in hepatocyte nuclei. The high DEVD-AFC activity may be attributable to 
caspase-7, which was previously showed to be activated in apoptotic hepatocytes 
(Jones et al., 1998). Taken together, these results show that PARP in the liver cannot 
be cleaved by caspase-3.
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Figure 27: Processing of caspase-3 in hepatocyte or thymocyte cell extracts.
Cell extracts were prepared from isolated hepatocytes incubated in the absence or 
presence o f 100 ng/ml anti-Fas antibody and isolated thymocytes incubated in the 
absence or presence o f 1 jjM  dexamethasone after 4 hours. Isolated nuclei were 
sonicated and urea extracted prior to SDS-PAGE analysis followed by 
immunoblotting as described in Materials and Methods.
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5.6 Discussion
The lack of PARP cleavage during apoptosis appears unique to the liver and has been 
reported not only in Fas-induced apoptosis (Jones et al., 1998), but also in TGF-P 
induced apoptosis in rat hepatocytes (Inayat-Hussain et al., 1997) and in human 
Hep3B hepatoma cells treated with topoisomerase-1 inhibitor (Adjei et al., 1996). 
The reasons for the lack of PARP cleavage during hepatocyte apoptosis appear to be 
two-fold. First, the intrinsic caspase activity for DEVD-selective cleavage in PARP 
was less in hepatocytes compared to thymocytes. This was reflected by the lower 
DEVD-AFC cleavage activity in hepatocyte extracts. Even after normalisation to 
DEVD-AFC activity found in apoptotic thymocytes, hepatocyte extracts were still 
less efficient at cleaving partially purified PARP. Secondly, PARP present in 
isolated mouse liver nuclei was resistant to cleavage by extracts fiom apoptotic cells 
even though the nuclei underwent apoptotic changes and also resistant to cleavage by 
recombinant caspase-3. This suggests that the absence of PARP degradation during 
hepatocyte apoptosis is not due to the absence of active caspase-3 or intracellular 
compartmentalisation of caspase-3 (Martins et al., 1997b).
In the absence of any evidence for multiple PARP isoforms arising fiom multiple 
genes or alternative splicing, the simplest explanation is that some post-translational 
modification occurs that hinders caspase mediated cleavage. Although PARP itself is 
auto-ribosylated during activation (Kleczkowska and Althaus, 1996), it is unlikely to 
account for the difference in proteolysis during apoptosis between PARP in the liver 
and PARP in other tissues. The possibility that phosphorylation may induce PARP 
resistant to proteolysis by caspases was explored by subjecting sonicated liver PARP
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or purified PARP to hyperphosphorylation by protein kinase A or dephosphorylation 
by alkaline phosphatase. Neither treatment affected the inability of caspase-3 to 
cleave liver PARP or its ability to cleave purified PARP (R.A. Jones and G.E.N. 
Kass, unpublished observations).
In conclusion, I report here that the DNA-repair enzyme, PARP present in mouse 
liver is precluded fi*om proteolytic cleavage by caspase-3 and related caspases. This 
appears to be due to a modification in liver PARP as well as an inefficient PARP 
processing machinery present in apoptotic hepatocytes.
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Chapter 6
General Discussion
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Work on Fas has generally focused on the immune system, though it has been shown 
that the FasR/FasL system is involved in various disorders such as thyroiditis 
(Giordano et al., 1997), diabetes (Chervonsky et al., 1997), AIDS (Hiromatsu et al., 
1994), lymphomas (Fisher et al., 1995) and fulminant hepatitis (Ogasawara et al., 
1993; Galle et al., 1995; Kondo et al., 1997). Currently little is still known about how 
apoptosis is controlled in many of the latter organs.
Hepatocytes express high levels of Fas, which has been shown in vivo by 
intraperitoneal injection of anti-Fas antibody in mice to result in the death of the 
animals through fulminant hepatitis like massive liver damage (Ogasawara et al., 
1993). Lymphocytic infiltration and apoptosis have both been suggested to mediate 
the destruction of hepatocytes and also possibly biliary epithelium in various 
hepatobiliary disorders (Mizuhara et al., 1994). There is an upregulation of the Fas 
receptor, especially in the periportal area, in the liver in patients with chronic virally 
induced hepatitis (Samanta et al., 1997). Mice with targeted mutations in the Fas 
gene showed substantial liver hyperplasia, which was accompanied by the 
enlargement of nuclei in hepatocytes (Adachi et al., 1995). This was also seen in 
humans showing mutations in the Fas gene. Thus, the Fas system seems to play a 
role in the apoptotic process to maintain homeostasis of the liver. Though much 
work has been undertaken into Fas-mediated liver damage, the signalling cascade 
induced by Fas in hepatocytes remains unclear.
Previous studies carried out in primary hepatocyte cultures have shown that Fas- 
induced apoptosis may occur in vitro (Galle et al., 1995; Ni et al., 1994; Rouquet et 
al., 1996a; Nishimura et al., 1997. However, cultured cells are very refractory to
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anti-Fas antibody treatment as compared to the in vivo situation where full 
destruction of the liver occurs within a few hours. Experimentally, the development 
of tools such as the anti-Fas antibodies and rapid cell quantification will continue to 
be invaluable and with this, the nature of the Fas and death machinery could be 
unveiled. Full understanding of the Fas system is likely to prove useful in providing 
insights into various human autoimmune diseases as well as Fas-mediated liver 
disorders.
The aims of this project was to establish a system which could be used to investigate 
the mechanism of Fas-mediated apoptosis in murine hepatocytes and then to use this 
to dissect out the role of intracellular mediators in the Fas signalling cascade. 
Isolated murine hepatocytes cultured in cell suspension system responded to 
stimulation in the same way as in vivo following intraperitoneal injection of anti-Fas 
antibody in mice. This system was then used to study the role of specific proteases 
and their substrates, which have been implicated in the Fas death machinery and to 
assess the involvement of other mediators such as specific kinases in the signalling 
cascade.
In this study, the isolated murine hepatocytes in cell suspension responded very 
differently from that of primary hepatocyte cultures to Fas-stimulation. Thus, this 
system was used to provide an in vitro system that in kinetic and magnitude terms 
resembled the in vivo situation where apoptosis is induced in the whole liver within a 
few hours following intraperitoneal injection of anti-Fas antibody (Ogasawara et al., 
1993). In agreement with other reports (Ni et al., 1994; Rouquet et al., 1996a; 
Rouquet et al., 1996b), the protein synthesis inhibitors cycloheximide and
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actinomycin D restored the ability of cultured hepatocytes to respond to anti-Fas 
treatment. These agents were shown not to alter the kinetics of freshly isolated 
mouse hepatocytes in suspension.
In order to elucidate the mechanism by which primary hepatocyte cultures are 
refractory to Fas-stimulation, this study examined the role of protein kinase 
inhibitors. The role of MAPK as a negative regulator of Fas-mediated apoptosis was 
investigated using the MEKl inhibitor PD089059. All MAPK pathways involve the 
same highly specific form of regulation involving other proteins such as ERKl/2, 
JNK/SAPK and p38 kinase. MEKl inhibition was shown to induce apoptosis in 
primary hepatocyte cultures in the presence of anti-Fas antibody with a similar 
kinetic profile to anti-Fas antibody in conjunction with cycloheximide. Indeed this 
study showed the induction of apoptosis with PD089059 in the absence of anti-Fas 
antibody implicating the involvement of ERKl/2 in the regulation of Fas-mediated 
apoptosis. This finding was supported by a recent report (Holmstrom, 2000) which 
showed that activation of ERKl/2 pathways by both physiological and exogenous 
ERKl/2 activators resulted in the suppression of both early and late features of Fas- 
mediated apoptosis in Jurkat cells. Pre-incubation of Jurkat cells with PD098059 
abolished the effect of all ERKl/2 activators that was also seen in TRAIL-mediated 
apoptosis. Thus, it would appear that ERKl/2 is activated in primary hepatocyte 
cultures, resulting in suppression of Fas-mediated apoptosis.
The role of PI-3K was investigated using the selective inhibitor of the p i 10 subunit, 
Wortmannin. The PI-3K inhibitors, Wortmannin and LY 294002 (Powis et al., 1994; 
Vlahos et al., 1994) inhibit ERKl/2 activation in response to several stimuli such as
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TCR, insulin, platelet-activating factor and growth hormone (Cross et ah, 1994, 
Welsh et ah, 1994; Ferby et ah, 1994; Urich et ah, 1995; Kilgour et ah, 1996; von 
Willebrand et ah, 1996; Sutor et ah, 1999). This data is further supported by studies 
demonstrating suppression of ERKl/2 activation by expression of dominant-negative 
PI-3K and activation of ERKl/2 by constitutively active PI-3K (Hu, Q. et ah, 1995; 
von Willebrand et ah, 1996; Sutor et ah, 1999). The results in this study showed the 
induction of apoptosis by Wortmannin, independent of Fas-stimulation, in primary 
hepatocyte cultures. Inhibition of PI-3K by Wortmannin has also been reported to 
increase caspase-3 like activity correlating to the down regulation of the survival 
protein bcl-2 (Mukasa et ah, 1997). PI-3K could induce the protein phosphorylation 
of members of the bcl-2 family via PKC. A recent study (Ruiz-Ruiz et ah, 1999) 
indicate the plausible mechanisms for PKC induced protection of Fas-mediated 
apoptosis in Jurkat cells. The first mechanism that is a result of moderate PKC 
activation would be ERK1 /2-dependent and the second that functions when PKC is 
maximally activated would be independent of ERKl/2 activation. Another recent 
study showed that concavalin A induced ERKl/2 activation induces expression of 
FLIP which then suppresses Fas-mediated apoptosis in Jurkat cells (Yeh et ah, 1998). 
However, the results from this study only allow the conclusion that Wortmannin 
inhibits a fundamental protein(s)/process(es) required for cell survival in cell culture. 
This study does not indicate whether hepatocytes in cell suspension require this 
pathway for survival.
A great deal of knowledge on the signalling cascade involved in Fas-induced 
lymphocyte apoptosis has recently emerged, and it is our current understanding that a 
self-amplifying cascade of caspases, of which caspase-8 is the apical protease, that
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are responsible for most if  not all apoptotic changes (Nicholson & Thomberry 1997). 
Although the exact molecular ordering of the events following caspase-8 activation 
remains to be fully established, caspase-3 appears to be a major death executioner in 
the Fas system (Nicholson et al., 1995; Slee et al., 1996). Through tripeptide and 
tetrapeptide inhibitor activity profiles and the cleavage of fluorogenic peptide 
substrates, my studies show that caspases related to the caspase-3 subgroup are major 
contributors to the execution phase of Fas-mediated apoptosis in freshly isolated 
murine hepatocytes (Jones et al., 1998). Caspase-3 is often viewed as a key effector 
of the cellular destruction during apoptosis (Nicholson et al., 1995) yet my study 
showed no detectable accumulation of the catalytically active form of caspase-3, 
unlike that of caspase-7. This finding suggests a more important role for caspase-7 in 
inducing apoptotic changes in Fas-simulated hepatocytes. The results from this study 
using tripeptide and tetrapeptide were consistent with previous reports. The inhibitor 
Ac-DEVD-CHO was shown to act primarily at the level of caspases related to 
caspase-3 and -1 (Margolin et al., 1997) whereas Z-VAD-FMK appeared to act on an 
upstream target (MacFarlane et al., 1997) possibly caspase 8 (Medema et al., 1997b). 
Caspase-8 has been shown to highly sensitive to Z-VAD-FMK (Medema et al., 
1997b) which corroborates its general potency as an inhibitor of Fas-mediated 
apoptosis. Previous reports have shown that the systemic use of caspase inhibitors or 
overexpression of bcl-2 has been found to protect animals from fulminant hepatitis 
and lethality induced through anti-Fas injection (Lacronique et al., 1996; Rodriguez 
et al., 1996; Rouquet et al., 1996b, Künstle et al., 1997) which further supports the 
important role of caspases in Fas-mediated liver cell apoptosis. A recent in vivo 
study showed that caspase-3 is required for hepatocyte Fas-mediated apoptosis by 
injecting caspase-3 deficient mice with anti-Fas antibody (Woo et al., 1999).
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The serine protease inhibitors DCI and TPCK, but not TLCK partially inhibited anti- 
Fas induced morphological changes as well as DNA fragmentation. Both DCI and 
TPCK have been previously shown to prevent anti-Fas induced apoptosis in Jurkat 
cells (Weis et al., 1995) as well as in other apoptotic systems (Weaver et al., 1993). 
My results show that DCI did not prevent fluorogenic caspase substrate cleavage 
activity whereas TPCK did, suggesting the contribution of possibly more than one 
serine protease in the apoptotic response (Jones et al., 1998). Owing to the fact that 
neither DCI or TPCK completely blocked Fas-mediated hepatocyte apoptosis unlike 
the peptide inhibitors of caspases, it would appear that caspases are the main 
executioners of apoptosis in response to Fas whereas the serine protease targeted by 
DCI and TPCK appear to accelerate the completion of the apoptotic response by the 
caspase cascade.
Hence my results showed that the mechanism of Fas-induced hepatocyte apoptosis 
involves caspases, in particular caspase-7 and possibly caspase-3, as well as a 
TPCK/DCI-sensitive serine-type protease(s) (Fig. 28). The following discussion 
looks at the involvement of mitochondria in this pathway. The role of mitochondria 
in the Fas-signalling cascade has been recently demonstrated (Bossy-Wetzel and 
Green, 1999), where caspases mediated cytochrome c release from mitochondria in 
Jurkat cells induced to undergo apoptosis by Fas-stimulation. This was previously 
demonstrated, where caspase-8 was shown to cleave BID, which on cleavage 
migrated to the mitochondria (Li et al., 1998). Recent studies have suggested that 
BID is a critical substrate in vivo which links the caspase cascade to mitochondrial 
release of cytochrome c (Nagata, 1999; Yin et al., 1999), and that there is
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mitochondrial release of caspase-2 and -9  during apoptosis (Susin et al., 1999). It 
has been recently shown that FasR-induced hepatocyte apoptosis in vivo involves the 
release of cytochrome c from mitochondria (El-Hassan and Kass, unpublished 
observation).
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An unexpected finding of my work was that despite strong evidence for the activation 
of caspase(s) able to process Z-DEVD-AFC in an Ac-DEVD-CHO sensitive manner, 
there was no cleavage of the DEVD motif-containing protein PARP. Most human 
caspases related to caspase-3 will process PARP to the 85kDa form (Nicholson et al., 
1995; Lazebnik et al., 1994; Alnemri, 1997; Nicholson and Thomberry, 1999). 
However, my results show that Fas-mediated apoptosis in freshly isolated murine 
hepatocytes does not result in PARP cleavage (Jones et al., 1998; Jones et al., 1999). 
Similar results were reported where induction of apoptosis in rat hepatocytes by 
TGpp also occurred in the absence of PARP cleavage (Inayat-Hussain et al., 1997) 
and in human Hep3B hepatoma cells apoptotically induced by topoisomerase 1 
(Adjei et al., 1996). The rationale behind the absence of liver PARP cleavage during 
Fas-mediated apoptosis was further investigated in my work using a cell-free system 
and as such is discussed below.
The reason for the lack of PARP cleavage during Fas-mediated apoptosis appears to 
be two-fold. First, the intrinsic caspase activity for DEVD-selective cleavage in 
PARP was less in hepatocytes compared to thymocytes. Pro-caspase-7 was fully 
processed to the catalytically active form, whereas caspase-3 was found to exist as 
p29 (lacking the pro-domain) with no detection of the active p l7  form. Even after 
normalisation to DEVD-AFC activity found in apoptotic thymocytes, hepatocyte 
extracts were still less efficient at cleaving partially purified PARP. Secondly, PARP 
present in isolated mouse liver nuclei was found to be resistant to cleavage by 
extracts from apoptotic cells even though the nuclei underwent apoptotic changes and 
were resistant to cleavage by recombinant caspase-3. Even distribution of isolated
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mouse liver nuclei did not result in PARP cleavage by recombinant caspase-3 or 
apoptotic cell extracts. These results suggest that the absence of PARP degradation 
during hepatocyte apoptosis is not due to the absence of active caspase-3 or 
intracellular compartmentalisation of caspase-3.
A possible explanation is that some post-translational modification occurs that 
hinders caspase mediated cleavage. The possibility that phosphorylation may result 
in PARP resistance to caspase proteolysis was investigated by subjecting sonicated 
liver PARP or partially purified PARP to hyperphosphorylation by protein kinase A 
or dephosphorylation by alkaline phosphatase. Neither of these treatments resulted in 
PARP cleavage either by caspase-3 or apoptotic cell extracts. Thus, it would appear 
that mouse liver PARP is resistant to proteolysis during apoptosis which might be due 
to post-translational modification as well as an inefficient PARP processing 
machinery present in apoptotic hepatocytes (Jones et al., 1999).
Investigations should be carried out to establish the role of protein kinases in the 
suppression of Fas-mediated apoptosis in primary hepatocyte cultures and to 
elucidate their interaction in the caspase cascade. This would give insight into the 
refractory nature of primary hepatocyte cultures and the involvement of the MAPK 
pathways, especially ERKl/2, JNK/SAPK and P1-3K in the Fas-signalling cascade. 
Also, other areas of interest would be protein synthesis and phosphorylation events 
and how these interact with the Fas-mediated apoptotic pathway. Further work is 
needed to fully dissect the caspase signalling cascade in Fas-mediated apoptosis in 
murine hepatocytes especially in relation to the emerging role of mitochondria. What 
was initially thought of as largely unimportant has been recently shown to play a
150
pivotal role in the apoptotic pathway acting as an adapter between the caspase 
cascade and end stage apoptotic events. Future work should address the nature of the 
TPCK/DCI-sensitive protease(s) and to establish their position within the caspase 
cascade activated by Fas. Finally, owing to the lack of mouse liver PARP cleavage 
during the apoptotic process in Fas-stimulated, further work would be needed to 
address why this is the case. This finding has only been shown in liver cells whereas 
in other cell types, PARP cleavage by caspases has been extensively demonstrated. 
Thus, it would appear that the nature of liver PARP precludes proteolysis by caspases 
and is not required for the apoptotic process and as such is worthy of closer 
inspection. The simplest explanation is that some post-translational modification 
occurs that hinders caspase mediated cleavage. Future work would help to elucidate 
what this modification(s) could be.
In summary, this study has shown that caspases and other proteases play an important 
role in Fas-mediated apoptosis in hepatocytes and that there is a series of safety 
mechanisms to regulate inappropriate cell death, involving protein synthesis and 
regulation of signalling cascades. The role of PARP in the mouse liver apoptosis has 
been shown not requisite to the apoptotic process unlike in other cell types. This 
study has yielded some insight into the signalling pathway of Fas-mediated apoptosis 
in the liver. Unravelling the Fas system in hepatocytes would elucidate the role of 
Fas in liver disorders which has medical treatment implications and as such this 
model can be used to that end.
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